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ABBREVIATIONS 
 
 
AB, Human AB serum 
APC, antigen-presenting cell 
CD154rVV, recombinant Vaccinia virus encoding CD154 
Ct, cycle threshold 
CTL, cytotoxic T cell 
DNA, desoxyribonucleic acid 
EBV-BL, Epstein-Barr-virus-transformed B lymphocyte 
ELISA, Enzyme Link Imuno-Sorbent Assay 
FCS, fetal Calf Serum 
FITC, fluorescein isothiocyanate 
GAPDH, glyceraldehyde-3-phosphate dehydrogenase 
GM-CSF, Granulocyte macrophage-colony stimulating factor 
HLA, human leucocyte antigen 
iDC, immature dendritic cell 
LPS, Lipopolysaccharides 
MHC, Major Histocompatibility Complexe 
MOI, Multiplicity of infection 
ORF, Open Reading Frame 
PBMC, peripheral-blood mononuclear cell 
PBS, phosphate buffer saline 
PE, phycoerythrin 
PHA, phytohemagglutinin 
qRT-PCR, quantitative Real-Time-Polymerase Chain Reaction 
RNA, ribonucleic acid 
rVV, recombinant Vaccinia virus 
TAA, tumor-associated antigens 
VV, Vaccinia virus 
WT, Wild-Type strain of Vaccinia virus 
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1. 
Introduction 
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The main focus of our group is the development of an anti-cancer therapeutic 
approach through the generation of tumor specific CD8 cytotoxic T cell responses, using as 
principal vaccine vector, recombinant Vaccinia virus expressing different molecules 
important to generate a cellular immune response. In order to further investigate the capacity 
of those vectors to provide ligands for different stimulatory pathways relevant in the 
generation of CD8+ T cell responses, we designed a recombinant Vaccinia virus expressing 
CD154 which plays an important role in the activation of different help-dependent immune 
responses. Our aim is to evaluate the capacity of a recombinant Vaccinia virus expressing the 
CD154 to enhance CD8+ T cell activation, in order to have a higher Tumor Associated 
Antigen (TAA) specific response. 
 
1. Cancer Immunotherapy 
 
1.1. Melanoma as tumor model 
 
Melanoma is a skin cancer resulting from malignant transformation of melanocytes. 
Melanocytes are located in the lower part of the epidermis (basal epidermal layer) of human 
skin and produce a pigment, the melanin, giving skin its color, whose production is increased 
following sun exposure. The melanomas are commonly classified depending on their 
anatomical location and stage of progression. This classification is also based on the presence 
of vertical growth, penetrating the upper and the underlying dermal layers. Primary  
melanomas are also detectable in districts other than skin where pigmented tissues are 
physiologically present, e.g. in the eye. Metastases may colonize skin and lymph nodes, or 
visceral sites like lung, liver, bone, brain and small intestine (Barnhill et al., 1993). 
Historically the word “melanoma” was used in 1812 by a Parisian physician called 
René Laennec, who described a disease exhibiting a dramatic rise in appearance in Europe, 
with a persistent worldwide annual increase in incidence of 3-7% per year in Caucasian 
populations with light-colored skin (Laennec R.T.H., 1812, Extrait au mémoire de M 
Laennec, sur les mélanoses, Bull. Ec. Soc. Med. 24). Later in 1857, William Norris published 
“Eight cases of melanosis with pathological and therapeutical remarks on the disease” (Norris 
W., 1857, Eight cases of Melanosis with Pathological and Therapeutical Remarks on that 
Disease, Longman: London). But, the one who first suggested that sunlight could play a role 
in melanoma formation was VJ Mc Govern in 1952 (McGovern V.J.,  1952, Melanoblastoma, 
Med. J. Aust., 139-142).  
Between the early 1960s and the late 1980s, the incidence of melanoma and the 
corresponding trend in mortality increased at a rate of 3-7% per year in populations of 
European origin. Increased incidence was continuous in all age groups, although showing 
moderation or cessation in younger people in more recent times (Armstrong et al., 1994). This 
increased incidence most for the thinnest melanomas and least for the thickest, like the 
moderation in mortality, is likely due to earlier diagnosis and better detection. Tumor 
thickness is the strongest predictor of survival with an almost linear correlation to the risk of 
death for tumor thickness up to 6 mm with no further increase in mortality for higher levels 
(Garbe et al., 1992). 
The usual risk factors for melanoma are represented by a blue eyes phenotype 
combined or not with blond or red hair, the presence of freckles on the skin and also the 
inability to tan, sun sensitivity, light complexion, and personal history of non-melanoma 
cutaneous cancer (Evans et al., 1988). Another well known risk factor is the number of nevi 
on the skin, directly correlated with the risk of malignant transformation (Garbe et al., 1994).  
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In particular, nevi need to be diagnosed following a precise classification taking into 
account asymmetry (not round or oval form), fuzzy margin, presence of different color in a 
same mole like brown, gray, black, red and blue, a size bigger than 5 mm or a growing nevus, 
and the convexness of the palpable mole. 
 However, the most critical process increasing the risk of developing melanoma is 
represented by intermittent and intense sun exposures for example during annual holidays in 
sunny areas with consequent sunburns in a high-risk phenotype, especially in childhood 
where UV radiation should be reduced (Langley et al., 1997). On the other hand, outdoor 
activities in childhood should be encouraged because they are associated with a lower risk of 
melanoma formation (Kaskel et al., 2001). 
The genetic background underlying susceptibility to melanoma was also addressed.  A 
recent study demonstrated that individuals living in Australia carrying a germ line mutation in 
CDKN2A gene, encoding the key melanoma suppressor protein p16INK4A, have a higher 
risk for melanoma. Mutated p16INK4A seems to be the most common cause of inherited 
susceptibility to melanoma (Bishop et al., 2002; Hussussian et al., 1994; Kamb et al., 1994). 
Because the main factor implicated in malignant transformation is an excessive 
exposure to ultraviolet radiation among Caucasians (MacKie, 1998), molecular events 
following UV radiation of skin were investigated. The UV radiation wavelength are divided 
in three groups: UVA, B and C. UVC (200-280 nm) is negligible in skin cancer development 
since it is prevented from reaching the surface of the earth by the atmospheric ozone layer that 
blocks UV light below approximatively 300 nm. UVA (320-400 nm) have longer wavelength 
and penetrate deeper into the skin than UVB, and pass through glass windows. Nevertheless, 
they are thousand times less effective at causing sunburns than UVB radiation. The UVB 
(280-320 nm) are considered to represent the most carcinogenic wave band. Indeed, nucleic 
acids and proteins absorb light within the UVB range, peaking at 260 nm and 280 nm 
respectively. This absorption of UVB by DNA causes damages that, if not repaired, can 
induce mutations causing skin cancer. The major UVB-induced photoproducts in DNA are 
the 6-4 photoproducts generated between adjacent pyrimidine residues, and pyrimidine 
dimers, formed specifically between adjacent thymidine (T) or Cytosine (C) residues (Figure 
1). This latter damage is more carcinogenic than 6-4 photoproducts because repaired less 
efficiently (Matsumura et al., 2002). 
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Treatments of melanoma is based on surgery to remove the tumor of all stages, 
chemotherapy, external and internal radiation therapy and biological therapy aiming at 
stimulating the ability of the immune system to fight cancer. Primary melanoma have 
excellent long-term prognosis following surgical removal. On the other hand, metastatic 
tumors have a severe prognosis with a median survival lower than 12 months and a 5 year 
survival of 5%. Thus, novel therapeutic approaches are urgently required for patients with 
metastatic melanoma. A promising approach may be represented by the use of agents that 
stimulate a tumor-specific immune response in combination with non specific immune 
modulators. 
 
1.2. Immunotherapeutic approach to stimulate tumor-specific response 
 
TAA provides the basis for specific cancer vaccines  (Brasseur et al., 1992; Dudley et 
al., 2003; Lethe et al., 1997; Rosenberg et al., 1988; Topalian et al., 1990; Traversari et al., 
1992; Vose et al., 1985; Yron et al., 1980). 
Human antigens can be classified in three groups. The first group is composed by the 
so called differentiation antigens expressed in melanoma and normal melanocytes. Tyrosinase 
(Robbins et al., 1994), MART-1/Melan-A (Coulie et al., 1994), gp100 (Adema et al., 1993) and 
TRP-2 (Noppen et al., 2000) belong to this group. A second group includes several families of 
antigens, so called cancer/testis antigens, expressed in cancers of different histological origin 
and testis, for example MAGE. MAGE genes are silent in all healthy adult tissues except 
testis and placenta (Takahashi et al., 1995). A third group is represented by antigens specific 
for individual tumors, resulting from mutations, deletions or recombinations. Accordingly, the 
clinical relevance of these antigens is usually limited to individual patients and are 
consequently not the most appropriate in our purpose. 
Cancer cells are by definition poor immunogens. However, it is possible to use, as 
vaccines, synthetic peptides whose sequences correspond to epitopes of TAA recognized by T 
lymphocytes. Notably, the clinical use of peptides alone is limited by their rapid proteolytic 
digestion, leading to limited bio-availability and poor immunogenicity. Optimal CTL 
activation depends on efficient antigen presentation by Major Histocompatibility Complex 
(MHC) molecules loaded through the class-I endogenous pathway of antigen processing  
(Maffei et al., 1997; Townsend et al., 1986; van Endert, 1999).  
There are different signals required for T cell activation. The primary mediators of 
immune reactivity are T and B lymphocytes. T lymphocytes have antigen-specific receptors 
that recognize MHC restricted epitope derived from processed antigens. Antigen-presenting 
cells (APC) activate naïve T cells by presentation of the antigen within major 
histocompatibility complex (MHC) antigens, the primary targets for allo-recognition.  This 
process requires binding of the antigen/MHC complex to the TCR/CD3 complex. This event 
initiates a cascade of signaling events that begins with the activation of several cytoplasmic 
protein tyrosine kinases. Recruitment of the CD4 or the CD8 associated tyrosine kinase, Lck, 
                                                             
Figure 1. Structure of the major UV-induced photoproducts in DNA. 
Absorbtion of UV light by DNA induces mutagenic photoproducts or lesions in 
DNA between adjacent pyrimidines [thymine (T), cytosine (C)] in the form of two 
main types of dimers. (a) Two adjacent T molecules (shown here), or an adjacent 
T and C residue, can be converted to a T–T or C–C cyclobutane pyrmidine dimer 
(CPD), respectively. The double bonds between C-4 and C-5 carbon atoms of any 
two adjacent pyrimidines become saturated to produce a four-membered ring. (b) 
In the other type of dimer, (6-4) photoproducts are formed between the 5' C-4 
position and the 3' C-6 position of two adjacent pyrimidines, either between TC 
(shown here) or CC residues. 
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into the vicinity of the TCR complex is believed to induce phosphorylation of CD3 proteins 
ultimately leading to downstream signal progression. However, in order not to lead to anergy, 
the activation of the T cells requires signaling not only through the T cell receptor (TCR; 
signal 1) but also through co-stimulatory pathways (signal 2). The candidate co-stimulatory 
molecules required for complete T-cell activation are T-cell surface molecules such as CD28, 
lymphocyte function-associated antigen-1 (LFA-1), CD2, CD30, CD44 and CD154. Each has 
the ability to augment the T-cell proliferative response to antigenic stimuli. It is likely that 
each of these acts through different mechanisms, some delivering co-stimulatory signals to 
the T-cell, some enhancing adhesion to APC, and still others mediating homing to target 
tissues (Lenschow et al., 1996). After activation, a number of cell surface and soluble 
molecules are known to regulate further the immune response (signal 3), like for instance T 
helper 1 cytokines such as IL-12 which plays an important role in CTL activation (Figure 2). 
Ag 
APC 
CD8+  
T cell 
Lck 
P 
of CD3 
SIGNAL 3 
SIGNAL 2  
Co-stimulation 
SIGNAL 1  
antigen binding and co-receptor ligation  
induces CD28 expression on T cell 
IL-12 
CD28 
CD80 
 
or CD86 
CD8 co-receptor 
MHC  
class I 
TCR/ 
CD3 
Figure 2. Requirements for T cell activation. 
T-cell activation requires signaling through the T-cell receptor (TCR) (signal 1) 
and co-stimulatory pathways (signal 2): for instance, antigen/MHC binding to the 
TCR and CD28 interaction with CD80 or CD86 expressed on the surface of APC. 
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Even if the idea of therapeutic anti-cancer vaccination is built on the theory that the 
immune system can control cancer, there are still some major obstacles: heterogeneity of 
tumor cells leading to the possible immune escape of tumor cells by  down-regulation or loss 
of β2-microglobulin, HLA Class I or TAA. Nevertheless, this approach is really promising 
and seems powerful. 
 
2. CD40/CD154 pathway 
 
2.1. CD40 
 
2.1.1. CD40 discovery 
 
CD40 was first described in 1985 as a putative 50 kD antigen associated with human 
urinary bladder carcinoma. This protein was also expressed on B lymphocytes and on some 
malignant B cells, especially in chronic lymphocytic leukemia, hairy cell leukemia and 
immunocytoma (Paulie et al., 1985). 
 
2.1.2. CD40 gene 
 
CD40 gene (11031 bases) maps to human chromosome 20q12-q13-2 (Banchereau et 
al., 1994) (Figure 3). 
 
 
 
 
 
Figure 3. Chromosomal location of CD40 gene (according to GeneLoc and/or HUGO, and/or 
LocusLink (NCBI build 31))  
CD40 geneon chromosome 20: start at 45,385,328 bp from pter, end at 45,396,915 bp from 
pter, size: 11,587 bases, orientation: plus strand. 
 
CD40 expression is controlled by post-transcriptional regulation through alternative 
splicing and at post-translational level. The CD40 gene contains 9 exons: the first ATG is 
located in exon 1 and the stop codon for translation in exon 9. Five alternative CD40 isoforms 
were identified by analyzing expression levels of CD40 mRNA by RT-PCR: CD40 type I to 
V. Structure of CD40 isoforme mRNA are summarized in Figure 4 (Tone et al., 2001). 
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2.1.3. CD40 protein 
 
  CD40 is a 277 amino-acids (30619 kDa) (Figure 5) glycoprotein (Armitage et al., 
1992) of 45-50 kD, member of the Tumor Necrosis Factor Receptor (TNFR) superfamily, 
expressed on the surface of specific cell types (Banchereau et al., 1994). The five mRNA 
isoforms are translated into five protein isoforms (Tone et al., 2001), as shown in Figure 6. 
Authors suggested that type I isoform normally signals through its endodomain resulting in 
define IL-12p40 gene expression, as oppose to type II and IV isoforms lacking this signaling 
endodomain, which might operate as dominant negative inhibitors by competing for CD154.  
B 
1 8 7 6 5 4 3 2 9 
ATG Stop 
AAA 
A 
 
9 
 
8 
 
7 
 
6 
 
5 
 
9 
 
8 
 
7 
 
6 
 
5 
 
9 
 
8 
 
7 
 
6 
 
5 
 
9 
 
8 
 
7 
 
6 
 
5 
 
9 
 
8 
 
7 
 
6 
 
5 V 
IV 
III 
II 
I 
Figure 4. Structures of CD40 mRNAs 
isoforms.  
(A) CD40 mRNA comprises sequences 
included in exons 1-9. Position of the first 
ATG and the stop codon for translation of 
CD40 are indicated. 
(B) Five alternative CD40 isoforms were 
identified by analysing expression levels of 
CD40 mRNA by RT-PCR: CD40 type I to V. 
Positions of alternative splicing are indicated 
by thick solid lines. The alternative splice site 
in exon 8 (5 bp downstream of the 5’ end of 
the exon 8) is indicated by dotted line. 
Position of Stop codons for translation are 
indicated by arrows heads. 
 
MVRLPLQCVLWGCLLTAVHPEPPTACREKQYLINSQCCSLCQPGQKLVSDCTEFTETECL 
PCGESEFLDTWNRETHCHQHKYCDPNLGLRVQQKGTSETDTICTCEEGWHCTSEACESCV 
LHRSCSPGFGVKQIATGVSDTICEPCPVGFFSNVSSAFEKCHPWTSCETKDLVVQQAGTN 
KTDVVCGPQDRLRALVVIPIIFGILFAILLVLVFIKKVAKKPTNKAPHPKQEPQEINFPD 
DLPGSNTAAPVQETLHGCQPVTQEDGKESRISVQERQ  
Figure 5. CD40 sequence (according FASTA data base).  
CD40 is a 277 amino-acids (30619 kDa) protein glycosylated member of the Tumor Necrosis 
Factor Receptor superfamily. 
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We now know that CD40 is a surface molecule expressed not only on B lymphocytes 
and on some carcinomas cell lines, but also on some epithelial cells (Armitage et al., 1992), 
dendritic cells (Moodycliffe et al., 2000), follicular dendritic cells, hematopoietic progenitor 
cells (Banchereau et al., 1994), vascular endothelial cells, fibroblasts and most of all, 
monocytes and macrophages (Maruo et al., 1997; Stout et al., 1996b; Stout et al., 1996a). 
CD40 expression is reviewed in the Table 1 (Grewal et al., 1998; Schonbeck et al., 2001a). 
 
Cell type Human Mouse 
B cells + + 
Dendritic cells + + 
Follicular dendritic cells 
- + 
Monocytes + + 
Macrophages + + 
Thymic epithelium cells 
- + 
Hematopoietic progenitor cells + - 
Carcinomas + - 
Endothelial cells + + 
Mast cells + + 
Fibroblasts 
- or + + 
Smooth muscle cells + - 
Eosinophils +  
Basophils +  
Epithelial cells +  
Keratinocytes +  
T cells (CD4+, CD8+, CD4+/8+, TCR+) +  
 
Table 1. CD40 expression 
 
Figure 6. Structures of CD40 isoforms.  
Structure presumed from amino acid sequences 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Type I II III IV V 
Cytoplasm 
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Like other receptors of the TNFR superfamily, CD40 presumably acts as a trimer 
receptor. Indeed, it has been demonstrated that, upon CD154 binding on its extracellular 
domain, CD40 forms at least a trimeric complex that is the minimal multimeric form 
sufficient to activate NF-κB (Ni et al., 2000; Pullen et al., 1999).  
CD40-initiated signals may result in multifaceted physiologic outcomes. In particular, 
this receptor activates signal transduction pathways other than NF-κB, like JAK/STAT, 
JunNterminal Kinase and Janus kinase. Indeed, Jak3, which is constitutively associated with 
CD40 by a proline-rich sequence in the membrane-proximal region of CD40, is activated by 
CD40 ligation and plays an important role in CD40-mediated function. This activation occurs 
through protein tyrosine phosphorylation (which is necessary for Jak3 as well as STAT3 
activation), even if CD40 lacks in intrinsic tyrosinase kinase activity (Hanissian et al., 1997; 
Leo et al., 1999).  
The cytoplasmic region of CD40 bears two major signaling domains (Hostager et al., 
1996; Inui et al., 1990). Accumulating evidence suggests that CD40 signaling requires the 
association of either or both domains with binding proteins TRAFs (TNFR-associated 
factors). The TRAF family consists of six known members, of which TRAF1, TRAF2, 
TRAF3 and TRAF6 directly, and TRAF5 probably via TRAF3/TRAF5 hetero-oligomers, 
associated with CD40 (Schonbeck et al., 2000; Schonbeck et al., 2001b). Stability of TRAF3 
may regulate the CD40-mediated activation of NF-κB, suggesting proteolysis of TRAF3 as a 
requirement for the CD40 mediated activation of this transcription factor (Annunziata et al., 
2000). Signaling pathway is summarized in figure 7 (Xu et al., 2004). 
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Figure 7. The role of CD40/CD154 interaction in cell immunoregulation. 
Once interacted with CD154, CD40 activates a secondary messenger by JAK/STAT pathway either by 
recruiting TRAFs which can activate the NF-κB pathway or even by other unknown pathways. 
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2.2. CD154 
 
2.2.1. CD154 discovery 
 
The CD154, also called CD40 ligand, gp39 or TRAP, was isolated and characterized 
in 1992 simultaneously by three different groups, as a ligand for CD40.  
A first group cloned a murine ligand for CD40 expressed on the cell surface of 
activated T cells and mediating B cell proliferation in the absence of co-stimulus as well as 
IgE production in the presence of IL-4 (Armitage et al., 1992). A second group identified a 
cell surface protein of approximately 39 kDalton expressed by activated T cells, a type II 
membrane protein with homology to Tumor Necrosis Factor (TNF) binding CD40 
(Hollenbaugh et al., 1992).  
A third group cloned TRAP (TNF-related activation protein), a ligand for CD40 
expressed on human T cells: a cDNA clone was isolated from a collection of T cell activation 
genes, and the structure features predicted a type II transmembrane protein also compatible 
with a secreted form. Human TRAP was highly similar to a murine CD40 ligand (82.8% 
cDNA identity and 77.4% protein identity between the murine CD40 ligand and the human 
TRAP) and bound a soluble CD40 construct (Graf et al., 1992). 
 
2.2.2. CD154 gene 
 
CD154 gene (12180 bases) maps in the q26.3-q27.1 region of the X chromosome 
(Figure 8) (Banchereau et al., 1994; Graf et al., 1992). Interestingly, since this gene contains a 
potential NF-κB binding site within its promoter at positions –1190 to –1181, regulation of its 
expression in primary human T cells is under NF-κB control (Srahna et al., 2001). 
 
Figure 8. Chromosomal location of CD154 gene (according to GeneLoc and/or HUGO, 
and/or LocusLink (NCBI build 33))  
CD154 gene on chromosome X: start at 133,675,149 bp from pter, end at 133,687,329 bp 
from pter, size: 12,180 bases, orientation: plus strand 
 
Human CD154 sequence is represented by a 1.8 kb mRNA containing an ORF coding 
for 261 amino-acids highly homologous to the mouse CD154 cDNA coding region. The 3’ 
non-coding region of the human CD154 mRNA contains AUUU repeats as well as a long 
stretch of 33 CA repeats (Gauchat et al., 1993), confering instability to mRNA (Shaw et al., 
1986).  
This mRNA instability is comparable to that of IL-2 mRNA (Ford et al., 1999; Rigby 
et al., 1999). p25, a protein capable of binding the CD154 3’UTR contributes to CD154 
mRNA instability. Another protein, p50, binding to a distinct site in CD154 3’UTR, is also 
involved in CD154 mRNA turnover. These proteins contact directly U and/or C in the 
conserved region (nucleotides 293 to 986) of the human CD154 3’UTR.  
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CD154 mRNA can be stabilized by PMA, which modulates the binding activities of 
p25 and p50, or by prolonged T cell activation. Decay of CD154 mRNA throughout T cell 
activation is uncoupled from T cell costimulation by CD28 signaling.  
Recently in 2003, regulation of CD154 mRNA stability by polypyrimidine tract 
binding protein (PTB) was exposed (Figure 9) (Hamilton et al., 2003). Indeed, CD154 3’UTR 
contains a novel cis-acting element whose function is determinate by the binding of PTB and 
PTB-T, an alternatively spliced PTB isoform. Importantly, p25 and p40 CD154 3’UTR 
binding proteins are related to PTB.  
All these mecanisms are excluded in our construct as UTR regions are not present. 
This confers to CD154 mRNA expressed by recombinant Vaccinia virus more stability, 
resulting in more protein translation. 
 
 
 
Figure 9. Model of CD154 mRNA stability regulation by PTB and PTB-T binding 
to the polypyrimidine-rich region in the 3’ UTR. 
PTB-T and PTB compete for binding to CD154 3’UTR and determine changes in 
mRNA stability. PTB is shown as a dimeric molecule that is primarily nuclear. PTB-T, 
which lack both the nuclear localization sequence and dimerization domain of PTB, is 
shown to be predominantly cytoplasmic and monomeric. 
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2.2.3. CD154 protein 
 
Human CD154 is a 261 amino-acids (29273 kD) type II membrane protein 
glycosylated (Gauchat et al., 1993) to an approximate MW of 33 to 39 kD. CD154 is 
expressed by activated T cells (Hollenbaugh et al., 1992) (Figure 10) and belongs to the TNF 
superfamily (Banchereau et al., 1994), showing 23.4% homology with TNF-α and 20.7% 
with TNF-β. Human CD154 has 5 cysteines as opposed to 4 cysteines for the mouse CD154. 
It consists of 22-residues intracellular N terminal domain, a short transmembrane segment, a 
relatively long, 65-residue extracellular ‘stalk’ and a globular TNF-like extracellular domain 
of about 150 residues at the C-terminal end (Karpusas et al., 1995). The transmembrane 
segment deduced from the hydrophobicity plot is followed by a protease cleavage site, which 
can represent a signal domain.  
 
Crystal structure of a soluble extracellular fragment of human CD154 was 
determinated in 1995 (Karpusas et al., 1995) (Figure 11). The CD40 binding site consists of a 
groove formed between the monomers and a mixture of both hydrophobic and hydrophilic 
residues on the surface of the binding site. Structural domains of CD154 implicate multiple 
functions (Andre et al., 2002a), for instance, by the presence of a Lysine-Arginine-Glutamic 
acid (KGD) motif. 
 
 
 
 
 
 
 
 
 
 
 
 
MIETYNQTSPRSAATGLPISMKIFMYLLTVFLITQMIGSALFAVYLHRRLDKIEDERNLH 
EDFVFMKTIQRCNTGERSLSLLNCEEIKSQFEGFVKDIMLNKEETKKENSFEMQKGDQNP 
QIAAHVISEASSKTTSVLQWAEKGYYTMSNNLVTLENGKQLTVKRQGLYYIYAQVTFCSN 
REASSQAPFIASLCLKSPGRFERILLRAANTHSSAKPCGQQSIHLGGVFELQPGASVFVN 
VTDPSQVSHGTGFTSFGLLKL  
Figure 10. CD154 sequence (according FASTA data base). 
CD154 is a 261 amino-acids (29273 kDa) glycosylated member of the Tumor Necrosis 
Factor superfamily. 
Figure 11. Crystal structure of a soluble 
extracellular fragment of human CD154 to 2 Å 
resolution. 
CD154 folds as a sandwich of two β sheets with 
jellyroll or Grey key topology. Molecule 
dimensions: 25å x 30å x 50å. The overall fold is 
similar to that of TNF-α and lymphotoxin-α. 
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Interestingly, it seems that CD154 molecules form trimers similar to those observed in 
the crystal structure of TNF-α and LT-α. Moreover, clustering of CD154 was demonstrated to 
be required for functional contact with CD40. CD154 clustering is mediated by an association 
of the ligand with p53, a translocation of acid sphingomyelinase to the cell membrane, and 
activation of the acid sphingomyelinase. The ensuing production of ceramide appears to 
promote the formation of ceramid-enriched signaling platforms that serve to cluster the 
CD154. Finally, it was demonstrated that CD40 clustering depends on reciprocal clustering of 
CD154 (Figure 12) (Grassme et al., 2002).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CD154 is mostly expressed on CD4+ T cells but also on some CD8+ T cells as well as 
basophils and mast cells (Banchereau et al., 1994). CD154 is also expressed on many other 
cell types reviewed in the table 2 (Grewal et al., 1998; Schonbeck et al., 2001a). Following T 
cell receptor triggering of CD4+ T cells in vitro, CD154 surface expression peeks at 8 hours 
following activation. Subsequently, the surface expression of CD154 is rapidly down-
regulated and is undetectable by 24 hours following stimulation (Yellin et al., 1994b). 
Dispersed CD40 monomers CD40 clustering 
Signalling 
B cell 
(intracellular) 
T cell 
(intracellular) 
Platform formation 
CD154 clustering 
p53 
CD154 
Vesicular 
ASM 
ASM 
Small rafts 
Vesicle mobilization 
Ceramide 
generation 
Raft-fusion 
Figure 12. Clustering of CD154 is required for the clustering of CD40. 
CD154 clustering is mediated by an association with p53, a translocation of acid 
sphingomyelinase (ASM) to the cell membran, and activation of ASM and the formation of 
ceramids. Ceramides appear to modify preexisting sphingolipid-rich membrane 
microdomains to fuse and form ceramid-enriched signaling platforms that serve to cluster 
the CD154, which functions as a prerequisite for CD40 clustering and, finally, CD40-
dependent signaling (Grassme et al., 2002). 
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Cell type Human Mouse 
Activated CD4+ T cells from spleen 
and blood + + 
Activated Th1 and Th2 clones 
- + 
Antigen primed lymph node cells 
- + 
PMA activated CD8+ T cells + - 
CD8+ T cell clones 
- + 
γδ TCR+ T cell clones - + 
NK cells 
- + 
Monocytes + + 
Macrophages +  
Fetal thymocytes 
- + 
Small intestine 
- + 
basophiles + - 
Mast cells + - 
Eosinophiles + - 
Activated dendritic cells + - 
Endothelial cells +  
Smooth muscle cells +  
Platelets +  
B cells and B cell lines  
(probably not physiological) + - 
 
Table 2. CD154 expression 
 
2.2.4. Soluble form of CD154: sCD40L 
 
CD154 also exists in a soluble form (sCD40L). CD154 is cryptic in unstimulated 
platelets but is expressed on the platelet surface within seconds after in vitro activation and 
during the process of thrombus formation in vivo (Henn et al., 1998). CD154 is then cleaved 
over a period of minutes to hours, generating a soluble fragment (sCD40L), released into the 
circulation (Aukrust et al., 1999) that remains trimeric (Andre et al., 2002a). sCD40L has the 
same tumor necrosis factor homology domain allowing
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Lysine-Arginine-Glutamic acid (KGD) motif, which remains part of the sCD40L cleavage 
product (Andre et al., 2002b).  
Its physiological role is, like TNF-α and IL-1, to induce endothelial cells to secrete 
chemokines and to express adhesion molecules, thereby generating signals for the recruitment 
and extravasation of leukocytes at the site of injury (Henn et al., 1998). The sCD40L released 
from platelets during thrombosis plays a key role in different steps of atherosclerotic lesion 
progression by inducing the production and release of pro-inflammatory cytokines from 
vascular cells and matrix metalloproteinases from resident cells in the atheroma. In 
thrombosis, sCD40L stabilizes platelet-rich thrombi, and in restenosis, it inhibits the re-
endothelialization of the injured vessel potentially leading to the activation and proliferation 
of smooth muscle cells. Studies on the cellular distribution of CD154 estimated that over 95% 
of sCD40L derives from platelets. This suggests that platelet stimulatory events must be 
considered in the biological and pathological context of CD154 function (Andre et al., 2002a).  
 
2.2.5. CD154 deficiency: clinical consequences 
 
Because interaction between CD40 and CD154 on activated T cells is critical for T-
cell-driven isotype switching (Fuleihan et al., 1993), CD154 involvement in X-linked hyper-
IgM syndrome was examined. This X chromosome-linked immunodeficiency is a rare 
inherited disorder (Hendriks et al., 1990) characterized by profound susceptibility to bacterial 
infections, increased susceptibility to opportunistic infections, very low or absent IgG, IgA 
and IgE, and normal to increased IgM and IgD serum levels (Callard et al., 1993; Korthauer et 
al., 1993; Ramesh et al., 1994). Pathologically, lymphoid tissues show disorganization of the 
follicular architecture and PAS positive plasmacytoid cells containing IgM. Lymph nodes 
lack germinal centers (Ramesh N, Geha RS, Notarangelo LD; New York: Oxford University 
Press, 1999, 233-40). Importantly, naturally occurring mutations of CD154 resulting in defect 
in CD154, induce a clinical severe immunodeficiency known as hyper-IgM syndrome or 
HIGM. Indeed, defective expression of the CD154 induces the failure of CD154 to interact 
with CD40 on functionally intact B cells, and this abnormality provides the molecular basis 
for immunoglobulin isotype switch defects observed in this disease (DiSanto et al., 1993; 
Fuleihan et al., 1993; Korthauer et al., 1993). 
Multiple lines of evidence support the view that, both CD154 on platelets and sCD40L 
are raised in patients with acute coronary syndromes (Garlichs et al., 2001; Heeschen et al., 
2003; Varo et al., 2003a), unstable angina (Aukrust et al., 1999) and myocardial infection 
(Garlichs et al., 2001; Schonbeck et al., 2001c; Varo et al., 2003a) as compared to patients 
with stable angina and controls. Patients with moderate hypercholesterolemia, a risk factor for 
cardiovascular disease associated with inflammation and hypercoagulability, show a 
significant increase of CD154 on platelets and in plasma or serum (Cipollone et al., 2002; 
Semb et al., 2003) and statin therapy was found to markedly decrease sCD40L levels 
(Cipollone et al., 2002). Cardiopulmonary bypass, inducing platelet activation and systemic 
inflammatory responses, causes an increase in plasma concentration of sCD40L, possibly 
contributing to thrombotic and inflammatory complications (Nannizzi-Alaimo et al., 2002). In 
addition, high levels of plasma sCD40L indicate a proinflammatory status in individuals with 
type 1 or 2 diabetes (Varo et al., 2003b), and blockage of sCD40L is known to prevent 
autoimmune diabetes (Balasa et al., 1997; Homann et al., 2002). Development of acute 
cerebral ischemia can also be mediated by the CD40 system. Indeed, patients with acute 
cerebral ischemia show upregulation of the sCD40L compared with controls (Garlichs et al., 
2003). After adjustment for other risk predictors, sCD40L level could be used as a predictive 
factor in cardiovascular diseases, diabetes and stroke.  
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2.3. CD40/CD154 interactions (Three-dimensional structure of a CD40/CD154 
interaction (McWhirter et al., 1999) is illustrated in Figure 13) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2.3.1. Regulation of APC activity 
 
Contact-dependent interactions between T cells and Antigen  Presenting Cells (APCs) 
providing bi-directional stimulatory signals are required for the initiation of successful T cell 
mediated immune responses. Based on the common model of T-cell activation (Janeway, Jr. 
et al., 1994), once MHC antigen complexes are presented by APCs to naïve T cells, the first 
antigen signal is delivered via the T-cell receptor/CD3 complex. In order not to lead to anergy 
(state in which T lymphocytes are alive but incapable of proliferating or transcribing IL-2 
gene in response to antigenic stimulation provided by APCs), but to T cell activation, this first 
signal must be followed by a second one passing through costimulatory molecules. Indeed, 
once primed, APCs express costimulatory molecules like for instance B7.1 (CD80) and B7.2 
(CD86), providing CD28 mediated costimulatory signals required for full T cells activation 
(Figure 2). 
Several studies have demonstrated that CD40/CD154 interaction was important in the 
induction of costimulatory activity on DCs and macrophages (Grewal et al., 1995; Grewal et 
al., 1996a). CD154 produces a prosurvival signal in DCs, and upregulates costimulatory 
molecule expression (CD80, CD86) enhancing antigen presentation by DCs. In turn, this 
interaction stimulates CD154+ helper and cytotoxic T cells by upregulating their IL-2 
receptor expression (Roy et al., 1995; Sin et al., 2001). Following CD154 activation, the 
activated DCs promote cell-mediated immunity by an increased production of TNF-α and IL-
12 activating neighboring DCs and T cells (Bleharski et al., 2001). 
Figure 13. Cristallographic representation of a 
CD40-CD154 interaction 
CD154 – promoted trimerization positions the 
CD40 intracellular domains to match the spacing 
between the receptor binding sites on the CD40 
trimer. 
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Similarly, CD40/CD154 interactions induce also dendritic cells to secrete an important 
set of cytokines and chemokines including also IL-8 and macrophage inflammatory protein-1 
alpha (MIP-1α) (Dubois et al., 1998). Nevertheless, the major interest in our context remains 
the effect of CD40 ligation on IL-12 secretion: IL-12 itself up-regulates CD154 expression on 
T cells and synergizes with IL-2 and with other co-stimulatory interactions including CD80 
and CD86, to maximize CD154 expression (Peng et al., 1998), IL-12 is a chemotactic 
molecule for macrophages (Ha et al., 1999), enhances CD8+ T cell homeostatic expansion 
(Kieper et al., 2001), and, in the presence of antigen, acts directly on the naïve CD8+ T cells 
to promote clonal expansion and differentiation (Curtsinger et al., 1999), rendering IL-12 
promissing adjuvant for cancer vaccination (Portielje et al., 2003). Similarly, IL-15 expressed 
by DC, monocytes and macrophages (Fehniger et al., 2001; Jonuleit et al., 1997), particularly 
after CD40 ligation on DC (Kuniyoshi et al., 1999) can be of major interest in our purpose: 
indeed, IL-15 is a potent chemoattractant for T cells (Wilkinson et al., 1995), promotes long-
term survival of anti-tumor cytotoxic T lymphocytes (Lu et al., 2002), and stimulates 
proliferation of human memory T cells. In the same way, GM-CSF secreted by monocytes 
and macrophages is induced by CD40 ligation (Aldinucci et al., 2002) and is crucial for DC 
development (Inaba et al., 1992). 
One major issue of CD40/CD154 interactions is the potential effect on apoptosis. 
Indeed, CD40 ligation inhibits spontaneous DC apoptosis (Ludewig et al., 1995), but also 
Fas/CD95-mediated apoptosis (Koppi et al., 1997).  
DC culture on CD154-transfected fibroblastic cells up-regulates the expression of bcl-
2 and, concomitantly, renders them virtually resistant to Fas-induced apoptosis. This suggests 
that upon encountering antigen-specific T cells, DC may become resistant to Fas-induced 
apoptosis (Bjorck et al., 1997).  
Finally, CD154 was demonstrated to inhibit tumor growth in a colon carcinoma 
model, but most of all, over-expression of CD154 on these tumor cells in vitro significantly 
decreased the level of tumor-induced DC apoptosis in a IL-12 independent manner (Esche et 
al., 1999). 
 
2.3.2. CD40/CD154 and B cells activation 
 
CD154 expressed on activated helper T cell membranes induces a number of B cell 
activation events. For instance, soluble CD40 inhibits T-dependant B cell proliferation (Lane 
et al., 1992), and a soluble fusion protein of CD40 and human immunoglobulin, CD40-Ig, 
inhibits entry of B cells into cell cycle, proliferation, and differentiation by activated Th1 and 
Th2, indicating that CD154 membrane protein expressed on activated helper T cells 
transduces T helper dependent B cell activation (Noelle et al., 1992). B cell proliferation 
induced by CD40 synergizes with  IL-4 receptor signaling (Brines et al., 1993). Nevertheless, 
CD40 ligation is necessary but not sufficient for the delivery of T help to B cells (Poudrier et 
al., 1994), meaning that B cells require a second signal besides CD40/CD154 to drive 
proliferation. By contrast, sCD40L alone is able to provide co-stimulatory signals to B cells 
(Hollenbaugh et al., 1992).  
CD40 signaling implication in B cell activation is also demonstrated by Lymphotoxin-
α (LT-α) expression in CD40 activated B cells. LT-α is a member of the TNF superfamily 
playing a role in CD40 mediated B cell activation (Worm et al., 1994). 
On the other hand, in particular situations, B lymphocytes can play an important role 
in antigen presentation (Constant et al., 1995; Kupfer et al., 1987; Rivera et al., 2001). 
Induction of optimal levels of T cell priming to an antigen requires the involvement of Ag-
specific B cells, in particular through the interaction of CD154 expressed on activated CD4+ 
T cells with CD40 on the surface of naïve B cells. This interaction results in rescuing B cells 
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from apoptosis induced by Fas or by surface IgM cross-linking by antigen (Lederman et al., 
1994; Tsubata et al., 1993; Valentine et al., 1992). Then, it up-regulates the co-stimulatory 
molecules CD80 and CD86 interacting with CD28 and CTLA-4 on the surface of activate T 
cells (Kaneko et al., 1996; Ranheim et al., 1994; Yellin et al., 1994a), providing more 
effective T cell costimulation (Ranheim et al., 1993). Finally, this interaction also increases 
the expression of other cell surface activation molecules like for instance CD23, CD54, 
CD95, and of adhesion molecules optimizing the effectiveness of B cell-T cell interaction. 
Indeed, signaling through CD40 on B cell surface, activates the CD1a/CD18 (LFA-1) 
intracellular adhesion system in B cells (Barrett et al., 1991). Furthermore, it induces LT-α 
secretion and promotes B cell growth and differentiation to plasma cells (Hanissian et al., 
1997; Ranheim et al., 1993; Schattner et al., 1995; Worm et al., 1994). 
 
2.3.3. CD40/CD154: Induction of Immuno-modulatory molecules 
 
Interleukin-6 (IL-6) is the major cytokine mediating antigen-driven B cell 
differentiation. CD154 may trigger IL-6 secretion by monocytes resulting in increased Ig 
secretion (Urashima et al., 1996). This effect is accompanied by an antibody isotype 
switching, as described above. Similarly, CD40 ligation induces TNF-α secretion that 
stimulates IgM (Hostager et al., 2002) and favors IL-10 secretion (Rogers et al., 2003). 
 On the other hand, stimulation of CD40 with purified soluble CD154 also induces 
pro-inflammatory responses in human monocytes, including secretion of IL-1β and IL-8. This 
suggests that ligation of CD40 on human monocytes may enhance or prolong inflammatory 
responses. This concept is reinforced by a study in which monocyte stimulation with a soluble 
murine CD8/human CD154 fusion protein increases the expression of cell-surface proteins 
including CD54, MHC class II, CD86 and CD40, demonstrating once again that CD40 plays a 
crucial role in the regulation of monocyte function, and in promoting inflammatory responses 
(Kiener et al., 1995). 
Ligation of CD40 on endothelial cells and smooth muscle cells induces the expression 
of leukocyte adhesion molecules such as vascular cell adhesion molecule-1 VCAM-1, E-
Selectin, and intracellular adhesion molecules ICAM-1 (Hollenbaugh et al., 1995; Karmann et 
al., 1995; Yellin et al., 1995), whereas CD40 ligation on macrophages triggers LFA-1 and 
also ICAM-1 expression (Kiener et al., 1995). In addition, ligation of CD40 on endothelial 
cells, smooth muscle cells, macrophages and T lymphocytes triggers expression and release of 
chemoattractants such as IL-8 (Simonini et al., 2000), MIP-1α (Macrophage Inflammatory 
Protein), MIP-1β, RANTES (Regulated on Activation, Normal T cell Expressed and 
Secreted), SDF-1 (Stromal cell-Derived Factor 1), and MCP-1 (Monocyte Chemotactic 
Protein) (Abi-Younes et al., 2000; Denger et al., 1999; Kornbluth et al., 1998; Nanki et al., 
2000; Thienel et al., 1999). These chemokines probably attract and direct T lymphocytes and 
macrophages, thus sustaining inflammation (Schonbeck et al., 2001).  
More important in our context, CD40/CD154 interactions, in combination with IFN-γ, 
foster Th1 immune response. Indeed, CD40 signaling appears to suffice for the induction of 
Th1-dominated, and the suppression of Th2-dominated, immune responses in vitro and in vivo 
(Ruedl et al., 2000). This function might involve suppression of IL-4 and induction of IL-
12p40 expression by endothelial cells, smooth muscle cells and macrophages (Lienenluke et 
al., 2000; Mosca et al., 2000). IL-12p40, dimerized with the IL-12p35 subunit, induces the 
production of IFN-γ, a cytokine that not only directly promotes Th1 responses, but further 
elevates CD40 levels, suggesting a positive feedback loop. IL-12 synergizes,  probably via 
enhanced expression of CD40 on monocytes and of IL-12 receptor on T lymphocytes, in the 
production of IFN-γ with IL-15, which is a potent stimulator of T-lymphocyte proliferation, 
thus accentuating Th1-predominant immune responses (Avice et al., 1998; Musso et al., 
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1999). Notably, IL-15 also increases the expression of CD154 on T lymphocytes (Mottonen et 
al., 2000; Skov et al., 2000) 
 
2.3.4. CD40/CD154: Role in development of B cell and CD8+ T cell memory 
 
CD40/CD154 interaction is involved in the development of B cell and CD8+ T cell 
memory. Indeed, mice lacking either CD40 or CD154, are not able to drive IgG, IgA or IgE 
antibody responses, but most of all, they are unable to generate germinal centers, where 
memory B cells develop. That indicates that costimulation of T cells through CD154 is 
critical for their differentiation into cells helping in the generation of B cells memory and of a 
mature antibody response (Foy et al., 1994; van Essen et al., 1995).   
CD40 ligation on APC leads to the secretion of IL-15, a potent chemoattractant for T 
cells (Wilkinson et al., 1995), which stimulates the proliferation of human memory 
(CD45RO+) CD4+ and CD8+ T cells (Kanegane et al., 1996). Thus, CD40/CD154 interaction 
may play an important role in the development of T cell memory. This hypothesis was 
confirmed in a study in which CD40 was capable of costimulating CD4+ T cell proliferation 
particularly in the CD45RO+ subset (Rogers et al., 2003). In addition, antiviral CD8+ T cell 
memory responses were defective in CD154-deficient mice (Borrow et al., 1996), suggesting 
a requirement of CD154-mediated signal in the establishment or maintenance of CTL 
memory. 
 
2.3.5. CD40/CD154 interactions and T cell activation and proliferation 
 
T cells can be modulated to different extents by different ligands, ranging from 
activation of signaling cascades, to cytokine secretion or target cell killing, and to T cell 
proliferation. 
CD154 ligation on CD40 induces the up-regulation of CD80 and CD86 molecules on 
antigen-presenting B cells that subsequently deliver costimulatory signals necessary for T cell 
proliferation and differentiation (Grewal et al., 1996b; Hollander et al., 1996; Yang et al., 
1996). These data opened the way for a novel strategy for the enhancement of T cell response 
in vivo based on CD40 mediated up-regulation of costimulatoty activity on APC, to fight 
infections and immunodeficiencies, and possibly to contrast tumor growth. 
This conclusion was consolidated by the fact that signaling through CD40 on the APC 
can replace CD4+ T-helper cells in priming of CD8+ CTL responses (Bennett et al., 1998; 
Schoenberger et al., 1998). CD40/CD154 interactions are therefore vital in the delivery of T-
cell help for CTL priming.  
Moreover, CD28 and CD154 were shown to play distinct and complementary roles in 
T cell activation, which may explain why blocking CD80/CD28 and CD154/CD40 
interactions have an additive effect in inhibiting T cell responses, illustrating that CD28 is 
critical for initiating T cell responses, whereas CD154 is required for sustained T helper 1 
responses (Howland et al., 2000). 
The possible roles of CD40/CD154 interaction in T-cell priming were investigated in 
CD154-deficient mice (Grewal et al., 1997). Lack of in vivo T-cell priming in CD154-
deficient mice was due to the limited expansion of antigen-specific T cells. Therefore, 
CD40/CD154 interactions may play a rate-limiting role in antigen-specific CD4+ T-cell 
priming and clonal expansion in vivo. Many studies have also focused on the important role of 
CD40/CD154 interaction in CD8+ T cell priming. Moreover, blockage of CD154 by in vivo 
administration of an anti-CD154 monoclonal antibody was shown to result in a profound 
inhibition of CTL priming that could be overcome by CD40 triggering. On the other hand, 
some results suggested strong CD8+ T cell priming activation following infection of CD154-
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deficient mice with lymphocytic choriomeningitis virus, suggesting that, in this case, priming 
of CD8+ T cells was independent of CD40/CD154 (Borrow et al., 1996; Oxenius et al., 1996; 
Ribas et al., 2001).  
In conclusion, it is known that the in vivo priming of CD8+ cytotoxic T lymphocytes 
(CTLs) responding to virally infected cells as well as allogenic cells or tumor cells generally 
requires the participation of CD4+ T-helper lymphocytes. The nature of this help has been 
further defined and shown to involve CD154 signals. For instance, CD154 up-regulation 
following MHC class II/peptide triggering on CD4+ T cells, results in the expression of 
CD154, which interacts with CD40 on DCs, resulting in increased MHC as well as co-
stimulatory molecules, CD80 and CD86 (Caux et al., 1994). These events “licences” DCs to 
activate CD8+ precursors by efficient cross presentation of MHC/peptide complexes (Ridge 
et al., 1998). Moreover, blockade of CD40/CD154 pathway inhibits CTL priming 
demonstrating the important role of CD40/CD154 interactions for the delivery of T-cell help 
during CTL priming (Bennett et al., 1998; Ridge et al., 1998; Schoenberger et al., 1998). 
 
2.3.6. Role of CD40/CD154 in human cancer 
 
CD40 is constitutively expressed on a wide range of cell types, but also on many type 
of human cancers cells, such as bladder, ovarian, colorectal, liver, lung, pancreas, prostate, 
cervical, breast carcinoma, acute myelomonocytic leukemia, HIV-related lymphomas, 
Hodgkin’s disease, low-grade B-cell malignancies and high-grade B-cell leukemia and 
lymphomas (Xu et al., 2004). This suggests that CD40 may play an important role in the 
process of tumor angiogenesis, development and progression. Indeed, CD40 is strongly 
expressed in the tumor endothelial vasculature of renal carcinomas (Kluth et al., 1997) and 
Kaposi’s sarcoma (Pammer et al., 1996). In addition, CD154 produced a large spectrum of 
growth-regulatory effects on CD40-expressing tumor cells, and in some cases, such as in 
Hodgkin’s disease (Clodi et al., 2002), CD40 activation by CD154 binding contributes to 
tumor survival and resistance to chemotherapy (Fluckiger et al., 1994; Johnson et al., 1993; 
Kluin-Nelemans et al., 1994). 
In contrast, CD40 cross-linking induced cell cycle arrest in murine and human B 
lymphoma cells, which was critical for the induction and maintenance of tumor dormancy 
(Marches et al., 1995). Similarly, ligation of CD40 on human breast cancer cells (Tong et al., 
2001) was found to produce a direct growth-inhibitory effect through cell cycle blockage 
and/or apoptotic induction with no overt side effects on their normal counterparts.  
Agonistic anti-CD40 mAbs, recombinant CD154 and CD154-transfected cells were 
used in experimental therapy of human cancer. Systemic in vivo administration of agonistic 
anti-CD40 mAb into tumor-bearing mice resulted in tumor eradication by CD8+ T cells (van 
Mierlo et al., 2002). Similarly, combination of agonistic antibody to CD40 and IL-2 induced 
complete regression of metastatic tumor in mice (Murphy et al., 2003), and anti-tumor 
immune responses derived from transgenic expression of CD154 in myeloma cells were also 
demonstrated (Liu et al., 2002). CD154-transduced tumor cells were used as a vaccine against 
B-cell lymphoma in mice model (Briones et al., 2002). These approaches were also already 
used in human clinical trials. For instance, clinical effects of recombinant CD154 protein 
were observed in solid tumors and in non-Hodgkin’s lymphoma. In phase I studies, soluble 
recombinant CD154 was administrated subcutaneously daily for 5 days, with encouraging 
anti-tumor activity including a long-term complete remission (Vonderheide et al., 2001; 
Younes, 2001). Similarly, an adenoviral vector encoding CD154 was well tolerated, in phase I 
clinical trials using infusion of transduced autologous leukemia cells (Kipps et al., 2000; 
Wierda et al., 2000): increased number of leukemia-specific T cells as well as reduction in 
leukemia cell count and lymph node size was demonstrated. 
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Potential side effects, however, should be carefully evaluated. For instance, efficacy of 
agonistic CD40-reactive mAb for clinical applications was limited by proinflammatory 
cytokine production by CD40-activated endothelial cells (Singh et al., 2001) and patients 
treated with recombinant adenovirus expressing CD154 transduced leukemia cells commonly 
experienced Influenza-like symptoms (Kipps et al., 2000). Nevertheless, CD154-based 
therapy alone or in combination with other therapies may offer an effective and safe strategy 
for the treatment of human cancers, auto-immune diseases and other CD40/CD154-associated 
diseases. 
 
3. Vaccinia virus as cancer vaccine reagent 
 
3.1. Properties 
 
3.1.1. Taxonomy 
 
Vaccinia virus is the most studied virus of the Poxviridae family. Although 
origine/natural host are not known, Poxviridae are divided in two subfamilies: 
Entemopoxviridae which are insect poxviruses and Chordopoxviridae which infect 
vertebrates. This last subfamily is divided in eight genus. The most common of them are 
Avipoxvirus including canarypox and fowlpox, Parapoxvirus and Orthopoxvirus. This last 
genus contains the most known and studied Poxviridae: cowpox, monkeypox, but most of all, 
Variola which causes smallpox and Vaccinia, used as a vaccine against smallpox. Several 
strains of Vaccinia virus are existing, some are replicating (Copenhaguen, Wyeth, WR, Lister, 
NYCBOH), others are in contrast highly attenuated strains unable to replicate or replicating 
poorly in human cells (MVA, NYVAC, ALVAC, TROVAC) (ICTVdB: universal virus 
database of the International Committee on Taxonomy of Viruses, Table 3).  
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Table 3. Taxonomic structure of Vaccinia virus. 
Vaccinia virus belongs to the Poxviridae family, to the Chordopoxviridae subfamily, and 
more precisely, to the Orthopoxvirus genus. 
(ICTVdB: universal virus database of the International Committee on Taxonomy of Viruses) 
 
3.1.2. Morphology 
 
Vaccinia virus particles are brick-shaped, measured 250 nm in diameter, are 250-300 
nm long and 200 nm high. The core is biconcave flanked by two lateral bodies (ICTVdB, 
Figure 14, 15 and 16), and this complex is surrounded by one or two lipidic envelope.  
To exit from cells, viral particles are propelled by a mechanism involving the 
cytoskeleton of the infected cells. The first indication that Vaccinia virus was able to interact 
with the cytoskeleton during its complex assembly process came from high voltage electron 
Subfamilies Genus Members 
1. Orthopoxvirus Buffalopox, camelpox, cowpox, 
monkeypox, rabbitpox, raccoon 
pox, tatera pox, vaccinia, variola, 
vole pox 
2. Parapoxvirus Chamois contagious ecthyma, 
Orf pseudocowpox, stomatitis 
papulosa 
3. Avipoxvirus Canary pox, fowlpox, junco pox, 
pigeon pox, quail pox, sparrow 
pox, starling pox, turkey pox 
4. Capripoxvirus Goatpox, sheeppox, lumpy skin 
disease 
5. Leporipoxvirus Hare fibroma, myxoma, rabbit 
(Shope) fibroma, squirrel fibroma 
6. Suipoxvirus Swinepox 
7. Molluscipoxvirus Molluscum contagiosum 
Chordopoxviridae (vertebrate 
poxviruses) 
8. Yatapoxvirus Tanapox, Yaba 
1.  A Melontha melontha 
2.  B Amsacta melontha 
Entemopoxviridae (insect 
poxviruses) 
3. C Chironimus luridus 
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microscopy studies which showed virus particles at the tips of large microvilli-like projections 
in infected cells (Strokes GV, 1976, J Virol, 18,636-643). Subsequent studies confirmed that 
these Vaccinia-tipped projections contained actin, as well as the actin cross-linking proteins 
α-actinin, filamin and fimbrin but not tropomyosin or myosin (Hiller et al., 1979; Hiller et al., 
1981). Indeed, Vaccinia virus induces the nucleation of actin tails from outer membrane 
surrounding the intracellular enveloped virus (IEV) (Cudmore et al., 1996). 
 
Figure 15. Electron micrograph of a thin-
sectioned intra-cellular vaccinia particle  
(Virology, BN Fields and DM Knipe) 
C: Core, L: Lateral body, E: outer membrane. 
C 
L E 
Figure 14. Vaccinia Virus particle  
(Dr. Milan V.Nermut of the National Institute for 
Biological standards and control. Herts, U.K) 
250 nm 
Figure 16. Schematic representation of a thin-
sectioned intra-cellular vaccinia particle. 
 
Envelop 
Lateral body 
Linear double stranded DNA cross linked at 
both termini 
RNA polymerase poly(A) polymerase 
capping enzyme methylating enzymes 
Nucleocapside or core 
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3.1.3. Nucleic acid 
 
Virions contain one molecule of linear double stranded DNA characterized by a 
naturally cross-linking at both termini of the two DNA molecules strands (Wittek, 1982). The 
total genome length of the Copenhagen strain of Vaccinia virus is 191,636 bp with a relative 
purin or pyrimidin bases composition of 66.6 % A/T. 198 “major” protein-coding regions and 
65 overlapping “minor” regions were identified, for a total of 263 potential genes (Goebel et 
al., 1990). In addition, the Vaccinia virus genome contains very long inverted terminal repeats 
of approximately 10 kbp which are further characterized by the presence of direct tandem 
repeats of a 70-base-pair sequence arranged in two blocks of 13 and 17 copies, respectively. A 
central region of the genome is highly conserved between different Orthopoxviruses. In 
contrast, the ends are hypervariable (Wittek, 1982). 
 
3.1.4. Cellular receptor for Vaccinia virus? 
 
Poxviruses can infect their hosts by different routes: through the skin by mechanical 
means, via respiratory tract (e.g., Variola virus infections of humans), or by oral route (Buller 
et al., 1991). Because one early gene of Vaccinia virus encodes a polypeptide related to EGF 
(Brown et al., 1985), the emergent question was whether EGF receptor (EGFR) may be a 
portal for infectivity. However, the expression of EGFR by target cells does not influence 
virus adsorption to cells or penetration (Hugin et al., 1994). Thus, the issue of an hypothetic 
receptor for Vaccinia virus remains to date open. 
 
3.1.5. Poxvirus replication  
 
Poxviruses replicate in the cytoplasm of infected cells and the cellular replication 
machinery is not essential since it is only present in the nucleus (Wittek, 1982). They encode 
most enzymes required either for macromolecular precursor pool regulations, or for 
biosynthetic processes (Buller et al., 1991). No origins of replication are known. Vaccinia 
virus follows then a “Self-priming” model for DNA replication summarized in Figure 17. 
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Figure 17. DNA replication in Vaccinia virus.  
Poxvirus DNA replication occurs in the cytoplasm, no origins of replication are known, the cellular 
replication machinery is not essential since it is only present in the nucleus. Self-priming model: 1-
6: Initiation at one end, formation of concatemers; 1-6’: Initation at the both ends. X and Y 
represent inverted terminal repeats, two isomers are  complementary. (inspired from K. Ballmer-
Hofer lecture at the University of Basel, Switzerland). 
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The general scheme of Vaccinia virus replication can be summarized in five steps. 
First, the attachment of the virion to the cell membrane is followed by the release of the core 
into the cytoplasm of the infected cells. At this stage, the transcription of the early genes 
begins under the control of early promoters, characterized by complete sets of single 
nucleotide substitutions. They consist of a 16 base-pair critical regions, separated by 11 base-
pairs of a less critical T-rich sequence (Davison et al., 1989a). During this early infection 
phase, early RNA are transcribed by the virion associated RNA polymerase (Wittek, 1982). 
This occurs a few minutes after infection and leads to early virion proteins production. Two to 
five hours after the beginning of the infection, the core which is now uncoated, liberates the 
viral DNA for the cytoplasmic DNA replication. Later in infection, late RNA are transcribed, 
under the control of late promoters. These consist of three regions: an upstream sequence of 
about 20 base-pairs, rich in T and A residues, separated by a spacer region of about 6 base-
pairs from a highly conserved (-1)TAAAT(+4) element within which transcription initiates 
(Davison et al., 1989b). Late RNA, which often contain self-complementary sequences, are 
very heterogeneous in length because there are no late stop transcription signals (Wittek, 
1982). These late mRNA lead to the production of late enzymes and virions proteins. These 
late virions proteins can be cleaved, glycosylated and phosphorylated by post-translational 
modifications. The last step of the replication leads to morphogenesis of new viral particles by 
assembling the early and late proteins and the newly synthesized DNA. The viral complex is 
then surrounded by lipidic envelopes. The first envelope consists, for some intracellular 
mature virus particles, in membranes derived from either the trans-Golgi network or tubular 
endosomes, resulting in intracellular enveloped virus which can be released upon lysis of the 
cell. A second enveloping process results from budding of intracellular mature virus particles 
through the plasma membrane (figure 18).  
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Figure 18. Assembly of Vaccinia virus in a human cell.  
SER = smooth endoplasmic reticulum; RER = rough endoplasmic reticulum. The assembly of vaccinia 
virus is a complex process that results in the formation of two infectious forms of virus: intracellular 
mature virus (IMV) and extracellular enveloped virus (EEV). (a) Vaccinia-virus morphogenesis starts in 
cytoplasmic ‘factories’ with the formation of membrane crescents, which extend to form spherical 
immature virus (IV) particles. (b) IV particles are non-infectious until they undergo morphological 
condensation into ‘brick-shaped’ IMV particles. IMV particles recruit the virus A27L protein (p14 kDa) 
onto their surface. (c) During infection, most IMV particles remain within the cell until they are released 
by cell lysis. However, some IMV particles become enveloped by membranes derived from either the 
trans-Golgi network (TGN) or tubular endosomes (d) to form intracellular enveloped virus (IEV) (e). (f) 
Proteins within the outer membrane of IEV particles induce the polarised, unidirectional polymerisation 
of actin, which propels the particle towards the plasma membrane and assists the infection of 
neighbouring cells. (g) During this process, the outer membrane of the IEV particle fuses with the plasma 
membrane of the cell, exposing an infectious particle on the cell surface and leaving proteins that induce 
actin polymerisation within the plasma membrane. (h) If these particles remain attached to the cell they 
are called cell-associated enveloped virus (CEV); (i) however, if they are released from the cell they are 
called extracellular enveloped virus (EEV). (j) In addition to the classical mechanism of vaccinia-virus 
assembly described above, EEV particles can also form via direct budding of IMV particles through the 
plasma membrane. This alternative mechanism of EEV formation might be facilitated by the transport of 
viral glycoproteins from the TGN to the plasma membrane (k) 
Expert Reviews in Molecular Medicine, 1999 Cambridge University Press, 
fig004cso. 
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The morphogenesis ends about 20 hours after the beginning of the infection (Figure 19). 
Figure 19.  Infection cycle of Vaccinia virus.  
1: attachment of the virion to the cell membrane, release of the core into the cytoplasme of 
the infected cell. 2: transcription of early genes. 3: DNA liberation from the core for the 
cytoplasmic DNA replication. 4: transcription of late genes. 5: morphogenesis of  new viral 
particles (Moss, B., Fields, B.N., Knipe, D.M. and Howley, P.M., Poxviridae: the viruses 
and their replication, 1996, Lippincott-Raven, Philadelphia, Vol. 2, pp. 2637-2671). 
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3.2. Vaccinia virus as a vector for therapeutic vaccination 
 
The global smallpox eradication in the early 1980 was made possible by vaccination 
with  Vaccinia virus, the vaccine, which could easily be produced in regional centers, and 
used in remote regions of the globe (Paoletti, 1996).  
In the first assay as cloning vector, a recombinant Vaccinia virus containing the 
thymidine kinase gene from Herpes simplex virus was generated, using in vivo recombination 
by co-transfection of eukaryotic tissue culture cells with cloned Bam-HI-digested thymidine 
kinase gene from Herpes simplex virus containing flanking Vaccinia virus DNA sequences 
(Panicali et al., 1982). Recombinant Vaccinia viruses were then developed as novel live 
vaccines (Smith et al., 1984). In vivo vaccination was then tested in the fox. Recombinant 
Vaccinia virus coding the rabies surface antigen gene was administrated to foxes, eliciting the 
production of titers of rabies-neutralizing antibodies equal or superior to those obtained  with 
conventional vaccines and conferring complete protection to severe challenge infection with 
street rabies virus (Blancou et al., 1986). Twelve years after, oral vaccination of foxes against 
rabies using recombinant Vaccinia virus as vector has led to the elimination of sylvatic rabies 
from large areas in western Europe (Pastoret et al., 1998).  
Vaccination using recombinant Vaccinia virus was also tested in human. Indeed, the 
first experimental immunization of human against the AIDS retrovirus was started in 1986, 
using recombinant Vaccinia virus expressing the complete gp160 env protein of HIV-1. This 
trial was the first report showing that immune state against HIV can be obtained in human 
(Zagury et al., 1988). 
Mimicking the endogenous pathway of antigen presentation by MHC class-I 
molecules by infection by recombinant viruses encoding multiple TAA could elicit tumor 
specific cell mediated immune responses possibly enhanced by the use of cytokines, or co-
stimulatory molecules such as CD80 and CD86 (Marti et al., 1997; Oertli et al., 2002). 
Viral vectors, to be used in humans, must have an extremely safe profile. This 
becomes even more relevant when recombinant viruses are used in cancer patients, who 
frequently show impaired immune defenses, as a consequence of their disease and/or 
treatments. Furthermore, viral vectors  should be able to infect both dividing and non dividing 
human cells and, particularly, human antigen-presenting cells such as dendritic cells or 
macrophages. Finally, viral vectors should, ideally, elicit limited anti-viral responses, thereby 
allowing for reiterated booster administrations (Bonnet et al., 2000). 
Even if Vaccinia showed some virulence and side effects (cutaneous complications, 
encephalitis, pathologic for the central nervous system) depending on the immune status of 
the vaccinee, during anti-variolic program, it may be considered as a highly attractive vector 
for cancer gene therapy. It has a large genome that can be engineered by recombination for 
the insertion and simultaneous expression of multiple genes. It has the capacity to 
accommodate large size inserts of 30 kb or more (Flexner et al., 1988). Vaccinia virus infects 
a large variety of cells. Importantly, recombinant viruses must retain the capacity to be 
produced on appropriate cell substrates and in adequate yields in spite of their attenuation 
profile. 
Vaccinia virus transcribes its genome by using viral enzymes and signals only. 
Recombinant foreign transcripts will be capped and polyadenylated by Vaccinia virus 
enzymes and will be translated into relatively high levels of recombinant protein within the 
infected cells.  
Although naturally cytopathic, this viral vector can be engineered to be non cytopathic 
but still infectious (Peplinski et al., 1998). Indeed, the cytopathic effect (CPE) of infection 
with poxvirus in general and Vaccinia virus in particular includes the induction of early cell 
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rounding, damage of the host genome and RNA, inhibition of host protein synthesis, and 
eventually, death of the infected cells (Bablanian et al., 1978). To develop better viral vectors 
non replicating and less cytopathic, Vaccinia virus were generated by treatment of cell-free 
Vaccinia viruses suspension with psoralen and long-wave UV light (PLUV) which is known 
to target nucleic acid and introduce chemical cross-linking in the viral genome, even at the 
minimal required doses (0.3 µg of psoralen per ml and 10 min of long-wave UV irradiation 
(Tsung et al., 1996)). Indeed, in the presence of long-wave ultraviolet light, psoralen 
derivatives photoreact with the nucleic acids within intact viruses and cells. This 
photoreaction can leave protein antigens and other surface components relatively unmodified, 
while eliminating the infectivity of a wide range of infectious agents (Hanson, 1992). Even if 
the inactivation kinetics are non linear as a result of photodegradation of psoralens, this 
overview confirms that psoralen-long-wave UV-inactivated viruses are useful as non 
infectious antigens for use in immunoassays and as successful experimental vaccines.  
Because the early phase of viral transcription is not affected by psoralen-mediated 
DNA cross-linking to the same degree as viral replication and late gene expression, the non-
cytopathic VV thus generated are able to infect cells and express small but not large reporter 
genes under early viral promoters for at least 3 days efficiently. Indeed, majority of cells 
infected with PLUV-VV are not killed and are able to continue proliferation. The function of 
certain early viral proteins induce early CPE and death of infected cells, which are blocked by 
this treatment. Inactivation of a gene by cross-linking is directly proportional to the size of the 
target gene and the dose of cross-linking reagents: limited cross-linking was able to inhibit 
viral DNA replication, probably by blocking the movement of viral DNA polymerase along 
the genome (Tsung et al., 1996).  
During a natural infection, Vaccinia virus life cycle remains completely within the 
cytoplasmic compartment of infected cells and ultimatly results with the cell lysis. Potential 
complications of integration into the host cell genome or phenotypic transformation can be 
excluded (Hruby, 1990). Furthermore, Vaccinia virus vectors are highly immunogenic, and 
induce humoral and cellular responses (Graham et al., 1991).  
Vaccinia virus is easy to produce since it replicates in primary cell cultures and many 
different cell lines (L929, CV-1, Hela) isolated from virtually any animal species (Hruby, 
1990). It is easy to inoculate (intradermal), has a high thermo-stability, and a transient 
expression (Jeremy W Fry and Kathryn J Wood, expert reviews in molecular medicine, 8 June 
1999, Cambridge University Press). Furthermore, it can be dried down, rehydrated and 
inoculated with only minimal losses in infectivity (Hruby, 1990). Most importantly, a 
recombinant Vaccinia virus may represent an “off-the-shelf” reagent, stable, with maintained 
infectious titer while frozen for many years.  
Based on all these characteristics, we chose Vaccinia virus as vector to engineer a 
cancer vaccine against melanoma. This virus was expressing two co-stimulatory molecules 
(CD80 and CD86) as well as three tumor associated antigens epitopes (gp100, MART-
1/Melan-A27-35, Tyrosinase1-9). The vaccine was successfully used in a phase I/II clinical trial 
in metastatic melanoma patients and demonstrated complete safety (Zajac et al., 2003). 
Remarkably, even if TAA specific responses were frequently induced by the viral 
administration, they tend to decrease over time. In order to improve the efficacy of this 
reagent, we tested the effect of CD154 expression by a recombinant Vaccinia virus in 
elicitation of tumor specific CTL responses in vitro. 
 
4. Aim of a vaccine based on recombinant Vaccinia virus expressing the CD154 
 
The main focus of our group is the development of anti-cancer therapeutic approach 
through the generation of tumor specific CD8 cytotoxic T cell responses. As principal vaccine 
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vector, we are using recombinant Vaccinia virus expressing different molecules important to 
generate a cellular immune response. 
Recombinant poxviruses expressing immunomodulatory molecules together with 
specific antigens might represent powerful vaccines for cancer immunotherapy (Bonnet et al., 
2000; Lattime et al., 1996). Furthermore, co-expression of CD80 and CD86 costimulatory 
molecules was demonstrated to increase the immunogenic capacity of a recombinant Vaccinia 
virus encoding melanoma tumor associated antigens (Mart-1/Melan-A27-35) (Marti et al., 
1997; Zajac et al., 1997). rVV encoding Mart-1/Melan-A27-35, gp100 and Tyrosinase1-9 Tumor 
Associated Antigens (TAA) and with CD80 and CD86 (Oertli et al., 2002; Spagnoli et al., 
2002) has been successfully used in a phase I/II clinical trial (Zajac et al., 2003). 
Nevertheless, even if specific responses to TAA were often induced after vaccination, these 
responses were limited in time and intensity. Therefore, we hypothezised that the 
immunological effect on APC and T cells of CD154 expressed by a recombinant Vaccinia 
virus could eventually improve the intensity and duration of T cell response. The following 
work performed in vitro, will mostly address the first issue. Our aim is to evaluate the 
capacity of a recombinant Vaccinia virus expressing CD154 to enhance CD8+ T cell 
activation, in order to obtain highly specific and sustained responsiveness. 
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Materials and Methods 
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1. MATERIALS 
 
1.1. Cells  
 
- CV-1: Monkey African Green kidney fibroblast, ATCC CCL70, ECACC Ref N°: 
87032605, grow rapidly and form monolayers of fibroblast like cells, cultured in DMEM 
10% FCS. 
 
- Vero: Monkey African Green kidney fibroblast-like, ECACC Ref N°: 84113001, cultured 
in DMEM 10% FCS. 
 
- EBV-BL: B lymphocyte transformed by Epstein-Barr virus, cultured in CM 10% FCS. 
 
- PMBC: Peripheral Blood Mononuclear Cell from healthy donor, cultured in CM 10% AB. 
 
- Human primary skin fibroblasts generated in our lab as previously described, cultured in 
DMEM 10% FCS (Zajac et al., 1998). 
 
1.2. Virus 
 
These experiments were done using the Copenhague strain of Vaccinia virus 
(generous gift of Dr. R. Drillien, Strasbourg, France). All the recombinant Vaccinia viruses 
used were produced from this strain, and were elaborated in the ICFS, Kantonsspital, Basel, 
Switzerland (Zajac P et al.). 
 
- WT: Wild-type Copenhague strain of Vaccinia virus, usually named as Control VV in our 
experiments. 
 
- CD154rVV: recombinant Vaccinia virus encoding the CD154 under early viral promoter 
control. CD154 gene was inserted in the A56R locus of Vaccinia virus genome by 
homologous recombination. 
 
1.3. Plasmids 
 
pKT1323 (generous gift from Dr.K.Tsung, St Louis, MO) (Map 1). 
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Map 1:  pKT1323 plasmid for the construction of CD154 encoding plasmid. 
(generous gift from Dr. K. Tsung (San Francisco, CA)) 
Escherichi coli guanine phosphoribosyl transferase (gpt) gene is used as a 
transient marker for selection of recombinant vaccinia virus, and amp gene as 
selection marker for further transfected bacteria. 
pKT1323 
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pKT1323-CD154: pKT1323 plasmid carrying the CD154 gene (Map 2). 
Map 2: CD154 encoding plasmid. 
CD154 gene was inserted into pKT1323 by BamHI and EcoRI ligation  
pKT1323-CD154 
  
 
38 
 
 
1.4. Buffers and media 
 
1.4.1. Buffers 
 
- HEPES Buffer Solution 1M (Invitrogen, Carlsbad, CA): 238.3 g/L, pH 7.2 to 7.5, pKa 7.3 
at 37°C. 
 
- MEM Non Essential AminoAcids (100x) without L-Glutamine  (Invitrogen, Carlsbad, 
CA). 
 
- Kanamycin solution (100x) (Invitrogen, Carlsbad, CA): 10 000 µg/ml kanamycin. 
Spectrum: Gram positive and gram negative bacteria. 
 
- GlutaMAX™-I supplement 200 mM (100x) (Invitrogen, Carlsbad, CA). 
 
- Trypsin-EDTA (1x) (Invitrogen, Carlsbad, CA): 0.5 g/L Trypsin (1:250), 0.2 g/L EDTA 
in Hanks’ BSS, without Ca2+ and Mg2+. 
 
- Phosphate-Buffer Saline (PBS) (1x) (GIBCO ™). 
 
- UltraPure™  10x TAE buffer (Invitrogen, Carlsbad, CA): 400 mM Tris-acetate, 10 mM 
EDTA at pH 8.3. 
 
- UltraPure™  10x TBE buffer (Invitrogen, Carlsbad, CA): 1 M Tris, 0.9 M Boric acid, 0.01 
M EDTA. 
 
1.4.2. Media 
 
- Dulbecco’s Modified Eagle’s Medium-low glucose (DMEM) (Fluka, BuchsSG, 
Switzerland). 
 
- RPMI 1640 Medium (Invitrogen, Carlsbad, CA). 
 
- CTL medium: RPMI 1640 Medium,1%  HEPES Buffer 1M, 1% Non Essential 
AminoAcids (100x), 1% GlutaMAX™-I (100x), 1% Kanamycine (100x), 10% filtrated 
human serum AB, IL-2 200 unit/ml final. 
 
- CM 10% AB (complete medium): RPMI 1640 Medium, 1% HEPES Buffer 1M, 1% Non 
Essential AminoAcids (100x), 1% GlutaMAX™-I (100x), 1% Kanamycine (100x), 10% 
filtrated human serum AB. 
 
- CM 10% FCS: RPMI 1640 Medium, 1% HEPES Buffer 1M, 1% Non Essential 
AminoAcids (100x), 1% GlutaMAX™-I (100x), 1% Kanamycine (100x),10% FCS. 
 
- DC medium: RPMI 1640 Medium, 10% FCS, IL-4 1000 unit/ml, rHuGM-CSF  50 ng/ml 
(LEUCOMAX®, 400 µg corresponding to 4.44 x 106 IU (Sandoz Pharmaceutical, 
Vienna, Austria)).  
 
  
 
39 
- DMEM 10% FCS: DMEM, 1% GlutaMAX™-I (100x), 1% Kanamycine (100x), 10% 
FCS. 
 
- Freezing medium: RPMI, 40% FCS, 10% DMSO  ((CH3)2SO, 78.13 D (Sigma Chemical 
co., St Louis, MO) 
 
- LB medium for agarose plate: LB Agar, powder (Lennox L Agar®, Invitrogen, Carlsbad, 
CA). 
 
1.5. Antibodies and tetramers 
 
- Soluble MHC-Peptide Tetramer streptavidin R-PE Conjugate, MHC allele: HLA-A 0201 
(ProImmune, Oxford, UK): MART-1/Melan-A37-35, EBV LMP2, EBV BMLF1, and 
CMVpp65 specific tetramer. 
 
- Mouse IgG antibodies to human CD154, CD83, CD80, CD86, CD8, CD4, CD1a, CD14  
and control IgG, R-PE or FITC conjugated (BD PharMingen, Franklin Lakes, NJ). 
 
- ch5D12 (generous gift from M. de Boer, Pan Genetics B.V., Utrecht, The Netherlands): 
chimeric antagonist anti-human CD40 monoclonal antibody were the mouse variable 
regions were placed on a IgG4 human backbone. 
 
1.6. Chemical 
 
Psoralen: (CN Biosciences, Nottingham, UK): 4’aminomethyl-trioxsalen (trioxsalen: 4,5’,8-
trimethylpsoralen): C15H15NO3. 
 
 
 
 
 
 
 
 
1.7. Primers and probes sequences 5’-3’ for quantitative Real-Time PCR 
 
vvI3L  Fwd CGG CTA GTC CTA TGT TGT ATC AAC TTC 
Rev TGC AAA GAA TTT GGA ATG CG 
Probe FAM-AGA AGC CGT CTA TGG AAA CAT TAA GCA CAAGG-
TAMRA 
 
TNF-α  Fwd CCC AGG GAC CTC  TCT CTA ATC A 
  Rev GCT ACA GGC TTG TCA CTC GG 
  Probe FAM-CTG GCC CAG GCA GTC AGA TCA TCT T-TAMRA 
  (Razeghi et al., 2001)  
O 
O O 
NH CH3 
CH3 
CH3 
CH3 
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IL-2  Fwd AAC TCA CCA GGA TGC TCA CAT TTA 
  Rev TCC CTG GGT CTT AAG TGA AAG TTT 
  Probe FAM-TTT TAC ATG CCC AAG AAG GCC ACA GAA CT-TAMRA 
  (Giulietti et al., 2001) 
 
IL-12p40 Fwd GCC CAG CTG CTG AGG AGA GT 
  Rev TGG GTG GGT CAG GTT TGA TG 
  Probe FAM-ACG GCA TCC ACC ATG ACC TCA ATG-TAMRA 
  (Yawalkar et al., 2000) 
 
IFN-γ  Fwd AGC TCT GCA TCG TTT TGG GTT 
  Rev GTT CCA TTA TCC GCT ACA TCT GAA 
  Probe FAM-TCT TGG CTG TTA CTG CCA GGA CCC A-TAMRA 
  (Kammula et al., 1999) 
 
GAPDH Fwd ATG GGG AAG GTG AAG GTC G 
  Rev TAA AAG CAG CCC TGG TGA CC 
  Probe FAM-CGC CCA ATA CGA CCA AAT CCG TTG AC-TAMRA 
(Martin et al., 2001) 
 
IL-6  Fwd CAG CCC TGA GAA AGG AGA CAT G 
  Rev GGT TCA GGT TGT TTT CTG CCA 
  Probe AGT AAC ATG TGT GAA AGC AGC AAA GAG GCA C-TAMRA 
 
CD154 Fwd GCT TTG AAA TGC AAA AAG GTG AT 
  Rev TTG TTT TAC TGC TGG CCT CAC TT 
 
Il-15 and GM-CSF primers and probe: Assays-on-Demand, Gene Expression Products 
(Applied Biosystems, Foster City, CA). 18S ribosomal RNA primers and probe: TaqMan® 
Ribosomal RNA Control Reagents, VIC™ Probe (Applied Biosystems, Foster City, CA). 
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1.8. Primers and probes concentrations for quantitative Real-Time PCR 
 
 
Primers and Probes concentration (nM) 
Gene 
Forward Reverse Probe 
vvI3L 200 200 200 
18S 50 50 12.5 
GAPDH 100 100 200 
CD154 100 100 0 
IL-12p40 200 400 200 
TNF-α 200 400 200 
IL-2 200 400 200 
IFN-γ 100 100 200 
IL-6 200 200 200 
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2. METHODS 
 
2.1. Cells isolation 
 
2.1.1. Peripheral-blood Mononuclear Cells (PBMC) isolation on Ficoll gradient 
 
Anticoagulated venous blood is layered onto ficoll  (HISTOPAQUE®-1077 (Sigma-
aldrich co., St Louis, USA), Polysucrose, 5.7 g/dl, sodium diatrizoate, 9.0 g/dl, density = 
1.077 ± 0.001 g/ml). During centrifugation, erythrocytes and granulocytes are aggregated by 
polysucrose and sediment; whereas, lymphocytes and other mononuclear cells remain at the 
plasma-ficoll interface. Erythrocyte contamination is negligible. Most platelets are removed 
by low speed centrifugation during the washing steps. Venous blood is collected in 
preservative-free heparin tubes, should be processed within 2 hours, and diluted 1:2 
depending upon absolute cell numbers to avoid gradient overloading. 
Principle: 
 
 
 
 
Technically,  15 ml blood is layered onto 12 ml ficoll and centrifuged 15 min at 400 x 
g at room temperature (lower temperatures may result in cell clumping and poor recovery). 
The opaque interface containing PBMC is collected, and cells are washed twice in one 
volume PBS by centrifugation (5 min, 250 x g). PBMC are resuspend in complete medium. 
 
2.1.2. Cells sorting using MACS magnetic MicroBeads  
 
For CD14+, CD8+ or CD4+ cells separation, PBMC are magnetically labeled with 
MicroBeads specific for CD14, CD8 or CD4 ((Miltenyi Biotec, Bergisch Gladbach, 
Germany), supplied as suspension containing 0.1 % BSA, 0.05 sodium azide, conjugated to 
monoclonal anti-human antibodies), and passed through a separation column which is placed 
in the magnetic field of a MACS separator (LS MACS separation columns, MidiMACS 
Separation Unit and MACS Multistand (Miltenyi Biotec, Bergisch Gladbach, Germany)). 
Columns capacity reaches a maximum of 2 x 109 total cells and 108 magnetically labeled 
cells. They have a hydrophilic coating allowing rapid filling. The column is washed with 
buffer before separation. The magnetically labeled cells are retained in the column while the 
unlabeled cells run through. After removal of the column from the magnetic field, the selected 
cells can be eluted as positively selected fraction. 
Technically, PBMC (in suspension in PBS) are pelleted, resuspended in 5 ml MACS 
buffer (PBS 500 ml, FCS 0.5 %, EDTA 2 mM, filterted) and centrifuged 5 min at 400 x g. 50 
µl MicroBeads per 107 total cells are added onto cells pellet, and gently mixed. After 15 min 
incubation at 4°C, cells are washed in MACS buffer and resuspended in 2 ml. 3 ml MACS 
buffer is applied on the column and let run through. This effluent is discard. Magnetically 
labeled cell suspension is applied on the column, and let run through. The effluent is collected 
as negative fraction. The column is washed twice with 3 ml MACS buffer and the effluent is 
collected with the same negative fraction. The column is removed from separator and placed 
FICOLL 
Mononuclear cells 
Plasma 
FICOLL 
Red cells 
Centrifuge 
15 min 400 x g 
Blood 
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on a new collection tube. 5 ml of MACS buffer are applied twice to the column and the cells 
are flushed out using the supplied plunger. Cells are pelleted by 5 min centrifugation at 400 x 
g and resuspended in complete medium. 
 
2.2. Cloning procedure for recombinant virus preparation 
 
2.2.1. Plasmidic DNA digestion 
 
1 µg plasmidic DNA is linearized for further cloning steps, by 1 hour digestion at 
37°C, using 10 units of appropriate restriction enzymes and buffers. 
 
2.2.2. Electrophoresis gel 1% agarose 
 
1g UltraPure™ Agarose (Invitrogen, Carlsbad, CA) is dissolved in 100 ml TAE 1x 
modified buffer ((Invitrogen, Carlsbad, CA), 40 mM Tris-acetate, 0.571 ml Glacial acetic 
acid, 0.1 mM Na2EDTA, pH 8.0, H2O qsp 50 ml). This buffer is formulated with a lower 
concentration of EDTA than standard TAE in order to minimize any interference by the 
EDTA on enzyme activity required for downstream applications. The gel is supplemented 
with 10 µg/ml BET ((Fluka Chemie AG, Buchs, Switzerland), 3,8-Diamino-5-ethyl-6-
phenylphenanthridinenium bromide, C21H20BrN3, 394.31 D), and poured in an electrophoresis 
support. DNA samples are mixed with 5 µl gel loading buffer, loaded and electric field (100 
mV) is applied. Results are observed under 365 nm UV light. 
 
2.2.3. DNA extraction from agarose gel slice 
 
The centrifugal filter device (DNA Gel Extraction Kit montage™ life Science kits 
(Millipore, Bedford, MA)) is designed to extract DNA fragments that are 100 to 10,000 bp in 
size from agarose gel slices in one 10 minutes spin. 
Technically, the DNA band of interest is located in the gel using a 365 nm UV lamp. 
The gel slice (under 100 µl in volume or 100 mg in mass) containing the DNA is cut out, 
placed in the Gel Nebulizer, spined for 10 minutes at 5,000 x g. The extruded DNA passes 
through the microporous membrane in the sample filter cup and is collected in the filtrate vial.  
 
2.2.4. Phenol/Chloroform extraction of nucleic acid: removal of contaminating 
proteins 
 
Phenol ((Sigma Chemical co., St Louis, MO), C6H5OH, 94.11 D) is added to DNA 
solution (v/v), vortexed 1 min and centrifuged 1 min at 8,000 x g. The nucleic acids remain in 
the aqueous supernatant, whereas the proteins stay in the interphase, and the phenol in the 
organic lower phase. The supernatant is collected avoiding any contact with the proteic 
interphase. A second extraction is performed on the resting phenolic phase to get out DNA 
eventually still present after the first extraction (100 µl H2O are added in the resting phenolic 
phase, vortexed 30 sec, centrifuged 1 min at 8,000 x g and the supernatant is collected as 
before). The two supernatants are mixed, and 1.5 volume of chloroform ((Sigma Chemical 
co., St Louis, MO), CHCl3, 119.38 D) is added to remove any traces of phenol. After 30 sec 
vortex and 1 min centrifugation at 8,000 x g, the supernatant containing the DNA is collected 
for further uses. 
 
2.2.5. Ethanol precipitation of DNA  
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For precipitation, 1/10 volume of NaAc 3M and 2.5 volume of ethanol 100 % are 
added on the DNA suspension, on ice. After homogenization, this mix is kept 15 min at –
70°C. After 15 min centrifugation at 4°C (500 x g), the supernatant is discarded and the pellet 
is dried. DNA pellet is then resuspended in 20 µl H2O. 
 
2.2.6. Ligation of a DNA fragment 
 
The plasmid and the DNA fragment to insert were previously digested by the two 
restriction enzymes of interest and precipitated. Opened vector, insert, buffer and 1 unit of T4 
DNA ligase (Invitrogen, Carlsbad, CA) are gently mixed. Simultaneously, a control ligation is 
done like previously but without insert, replacing it by the same volume of H2O. These two 
ligations are incubated 2 hours at room temperature and used for transformation. 
 
2.2.7. Escherischia coli transformation by electroporation 
  
One aliquot of Top10 Electrocompetent E. coli ((Invitrogen, Carlsbad, CA), 
transformation efficiency ≥ 1 x 109 cfu/µg supercoiled DNA, genotype: F-mcrA ∆(mrr-
hsdRMS-mcrBC) φ80lacZ∆M15 ∆lacX74 deoR recA1 araD139 ∆(ara-leu)7697 galU galK 
rpsL (StrR) endA1 nupG) stored at –70°C is thaw on ice. 1.5 µl of ligation is placed into an 
electroporation cuvette ((BIO-RAD, Hercules, CA), Gene Pulser® Cuvette, 0.2 cm) and 20 µl 
of E. coli are added onto the DNA. After 30 sec incubation on ice, the cuvette is perfectly 
dried and submitted to an electric choc (2.5 Volts, 200 Ω resistance, 25 µFD capacitance) in 
an electroporation machine.  
The bacteria are resuspended in 600 µl LB medium (Lennox L Agar®, (Invitrogen, 
Carlsbad, CA)) and incubated 1 hour at 37°C. 200 µl of transformed E. coli are spread on a 
Petri dish (100 mm x 15 mm polystyrene bacteriological Petri dish, 56.5 cm2 (BD Biosciences 
FALCON™, San Jose, CA)) containing LB medium and 1 unit/ml carbenicillin (α-
Carboxybenzylpenicillin disodium salt, C17H16N2Na2O6S, 422.4 g/mol. Spectrum: Gram-
positive and -negative bacteria, Pseudomonas (Fluka, BuchsSG, Switzerland)). The petri dish 
is incubated over night at 37°C. Single colonies are picked up with a sterile tip and put in 
culture in 2 ml LB medium at 37°C overnight under agitation. 
 
2.2.8. Plasmidic DNA isolation  
 
Plasmidic DNA is liberated from E. coli by SDS/alkaline lysis. SDS precipitate and 
cell debris are pelleted by centrifugation, and supernatant is loaded onto the NucleoSpin® 
Plasmid column (Macherey-Nagel, Düren, Germany). Plasmidic DNA binds to the silica 
membrane. After one wash with ethanolic buffer, DNA is eluted under low ionic strength 
conditions with alkaline buffer (5mM Tris-Cl, pH 8.5). 
Technically, E. coli (1-5 ml culture) are pelleted (30 sec, full speed), resuspended in 
250 µl A1 buffer and lyzed by 250 µl A2 buffer (5 min, room teperature). Cells debris are 
precipitated by adding 300 µl A3 buffer and pelleted by centrifugation (10 min, full speed). 
The supernatant is loaded on the column and centrifuged (1 min, full speed). The column is 
washed with 600 µl ethanolic buffer and the silica membrane is dried by 2 min centrifugation 
at full speed. 50 µl alkaline buffer are added on the column. After 1 min incubation, plasmid 
DNA is eluted by 1 min centrifugation at full speed. 
 
2.3. CD154rVV construction 
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2.3.1. PCR amplification of specific cDNA 
 
Human PBMC from healthy donor were stimulated (PHA 5 µg/ml, 10 units/ml IL-2) 
for 24 and 48 hours. Cells were collected, washed and total RNAs were extracted. After 
DNase treatment and Reverse Transcription, CD154 cDNA was PCR amplified, using the 
following primers: 
 
BamHI-CD154-5’: 
CTCGAGGGATCCATGATCGAAACATACAAC 
 
EcoRI-CD154-3’: 
CGAATTCTCAGAGTTTGAGTAAGCCAAAGGAC  
 
Technically, 2 µl cDNA were mixed with 2 µl PCR buffer 10x, 0.8 µl MgCl2, 1.6 µl 
dNTP (2.5 mM each), 1 µl BamHI-CD154-5’ 10 µM, 1 µl EcoRI-CD154-3’ 10 µM, 1 µl 
TaqPolymerase and 10.6 µl H2O. After PCR (5’ at 95°C, (1’ at 94°C, 2’ at 72°C)30x, 10’ at 
72°C, ∞ at +4°C), totality of  PCR products were loaded on a 1% agarose gel.  
 
2.3.2. Proteinase K treatment 
 
In order to eliminate contaminating proteins, CD154 cDNA was treated with 
proteinase K (50 µl cDNA are incubated with 3 µl EDTA 100mM, 3 µl SDS 10%, 1.2 µl 
TRIS 0.5 M pH 8.0 and 6 µl Proteinase K at 0.5 mg/ml for 15’ at 37°C). The enzyme was 
then inhibited at 65°C for 20’. After Phenol/Chloroform extraction, DNA encoding CD154 
was ethanol precipitated. 
 
2.3.3. Contruction of plasmid encoding CD154 
 
CD154 cDNA fragment was digested for 1 hour at 37°C with BamHI (Cut: 5’ G  
GATCC 3’ (Invitrogen, Carlsbad, CA)), then with EcoRI (Cut: 5’ G  AATTC 3’ (Invitrogen, 
Carlsbad, CA)) restriction enzymes. The digested fragment was isolated on a 1% agarose gel, 
extracted, precipitated and resuspended in 25 µl H2O. Same digestion steps were performed 
on pKT1323 (Map 1): this vector was digested at first with BamHI (3 µl plasmid, 2 µl 10x 
Buffer supplied with the enzyme, 1.5 µl BamHI restriction enzyme, 15 µl H20: 1 hour at 
37°C). Digestion was verified on 1 µl on an 1% agarose gel. On the previous digestion, we 
performed EcoRI digestion (previous 20 µl digestion, 1 µl 10x buffer supplied with the 
enzyme, 9 µl H20, 1.5 µl EcoRI: 1 hour at 37°C).  
The double digestion was verified on a 1% agarose gel, by loading totality of the 
digestion mix. The open plamid was cut out from the gel, extracted, ethanol precipitated and 
resuspended in 25 µl H2O. The open plasmid and the digested CD154 cDNA were ligated 
following the ligation protocol described in materiels and methods. In order to verify ligation 
efficacy, ligation product and native plasmid were digested by SacII (Cut: 5’ CCGC  GG 3’ 
│←BamHI→│ 
│←EcoRI→│ 
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(Promega, Madison, WI)). Indeed, only the native plasmid or the plasmid that did not 
integrate the insert will be cut by this enzyme (Map 1 and 2).  
Electro-competent Escherichia coli were transfected following the described protocol, 
with this ligation product or with the native plasmid as control. As 100 µl of vector displayed 
as expected very few colonies (2 single colonies only), 100 µl of the ligation product 
displayed ≈ 700 colonies, whereas 10 µl of ligation product displayed 70 colonies. Nine of 
those colonies and 1 of the colonie of the control plate were picked up. These colonies were 
grown over night at 37°C under agitation in 2 ml LB medium. Plasmid were extracted from 
these bacterial cultures using DNA NucleoSpin® plasmid.  
 
2.3.4. Directed Mutagenesis  
 
In vitro site-directed mutagenesis is an invaluable technique allowing site-specific 
mutation for carrying out vector modification. The QuickChange™ Site-Directed 
Mutagenesis Kit (Stratagene, Cambridge, UK) used in our context allows site-specific 
mutation in virtually any double-stranded plasmid, thus eliminating the need for subcloning 
into M13-based bacteriophage vectors and for ssDNA rescue. It requires no specialized 
vectors, unique restriction sites, or multiple transformations.  
It is used to make point mutations, switch amino acids, and delete or insert single or 
multiple amino acids, using PfuTurbo® DNA polymerase, which replicates both plasmid 
strands with high fidelity (this enzyme has 6-fold higher fidelity in DNA synthesis than Taq 
DNA polymerase), and without  displacing the mutant oligonucleotide primers. 
The oligonucleotide primers, each complementary to opposite strands of the vector, 
are extended during temperature cycling by PfuTurbo® DNA polymerase. Incorporation of 
the oligonucleotide primers generates a mutated plasmid containing staggered nicks. 
Following temperature cycling, the product is treated with DpnI. The DpnI endonuclease 
(target sequence: 5’-Gm6ATC-3’) is specific for methylated and hemimethylated DNA and is 
used to digest the parental DNA template and to select for mutation-containing synthesized 
DNA. DNA isolated from almost all E. coli strains is dam methylated and therefore 
susceptible to DpnI digestion. The nicked vector DNA containing the desired mutations is 
then transformed into XL1-Blue supercompetent cells. The high fidelity of the PfuTurbo® 
DNA polymerase, and the low number of thermal cycles contribute to the high mutation 
efficiency and decreased potential for generating random mutations during the reaction. The 
principle is summarized figure 20. 
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Figure 20. Overview of the principle of the QuickChange™ Site-Directed 
Mutagenesis Kit (Stratagene, Cambridge, UK) 
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2.4. Virus preparation 
 
2.4.1.  Cell infection 
 
Cells of interest are resuspended in medium complemented with FCS to avoid 
interactions with human anti-Vaccinia virus antibodies, present in human serum. Cells are 
counted and distributed in tubes or wells. Adherent cells are cultured 4 hours at 37°C. The 
excess of medium is aspirated and a minimal volume of medium is left on the cells to avoid 
drying. Cells growing in suspension are pelleted and resuspended in 200 µl medium. Viral 
solution is thaw and sonicated 1 min. The virus adsorb to the cells during 1 hour incubation at 
37°C. Adherent cells are regularly slowly agitate to avoid cell drying. Cells are washed once 
with PBS and appropriate medium is added. 
 
2.4.2. Recombinant Vaccinia virus construction  
 
2.4.2.1. General principle 
 
Recombinant Vaccinia virus are generated by homologous recombination with 
cotransfectant “VV plasmid”. 
This plasmid contains multiple expression/insertion cassettes containing early 
promoters (Davison et al., 1989a) and a multiple cloning site with the VV early transcriptional 
termination sequence (TTTTTNT) located downstream. The expression/insertion cassettes are 
flanked by sequences being identical to different viral loci and allow homologous 
recombination and production of rVV. The gene encoding the Escherichia coli guanine 
phosphoribosyl transferase (gpt) is used as a transient marker for selection of rVV (Falkner et 
al., 1990). This plasmide encoding the gene of interest is inserted by homologous 
recombination into the Wild Type strain (WT) of Copenhagen Vaccinia virus. Recombinant 
viral clones are selected according to their transient expression of the E. coli gpt marker under 
the selective pressure of mycophenolic acid (MPA), xanthine, and hypoxanthine as described 
(by Earl P.L. and Moss B. in “Current Protocols in Molecular Biology, pp 16.15.1-16.18.10. 
Greene Publishing, New York, 1995).  
 
2.4.2.2. Vaccinia virus growth inhibition by mycophenolic acid (MPA) 
 
The mycotoxin MPA (mycophenolic acid) is an inhibitor of purine metabolism. It 
inhibits the enzyme inosine monophosphate dehydrogenase and thereby prevents the 
formation of xanthine monophosphate. This results in the intracellular depletion of purine 
nucleotides and in an inhibition of cell growth (Mulligan et al., 1981). This MPA was 
demonstrated to reversibly block formation of Vaccinia virus plaque (Falkner et al., 1988). In 
addition, MPA is non mutagenic in the Ames test and in the related SOS test (Reiss, 1986): 
avoidance of mutagens should ensure virus stability. 
 
2.4.2.3. Recombinant Vaccinia viruses selection system based on expression 
of the Escherichia coli guanine phosphoribosyl transferase (gpt) gene 
 
The inhibition of the de novo synthesis of purines by MPA can be overcome by a cell 
that expresses the Escherichia coli gpt gene, which codes for the enzyme xanthine-guanine 
phosphoribosyltransferase (XGPRT), in the presence of xanthine and hypoxanthine in the 
growth medium (Mulligan et al., 1981).  
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The block of purine synthesis by MPA can also be overcome by a recombinant virus 
expressing the bacterial XGPRT (encoded by the Escherichia coli gpt gene). Indeed, synthesis 
of XGPRT enabled only the recombinant viruses to form large plaques in a selective medium 
containing MPA, xanthine and hypoxanthine (Falkner et al., 1988). 
In their experience, all plaques picked at the first selection step contain recombinants. 
Any contaminating wild-type virus or an accidentally picked microplaque is removed by 
further rounds of plaque purification in selective medium, and no background of 
spontaneously occurring gpt+ virus would be expected or has been observed. In addition, the 
gpt gene was incorporated into a plasmid vector that has a Vacinia virus promoter and unique 
restriction endonucleases sites for insertion of a foreign gene. Because of Vaccinia virus-
derived flanking sequences, the entire selection-expression cassette is inserted as a unit into 
the Vaccinia virus genome by homologous recombination. Thus, all of the Gpt+ recombinants 
analyzed also contained the foreign gene that had been inserted into the plasmid vector. 
 
2.4.2.4. Technical procedure 
 
Briefly, the plasmid containing the gene of interest is resuspended in 100 µl OPTI-
MEM®I medium without serum (Invitrogen, Carlsbad, CA). 10 µl Lipofectamine 
(LIPOFECTAMINE™ Reagent (Invitrogen™ life technologies, Carlsbad, CA)) is combined 
with 100 µl of OPTI-MEM®I medium and mix gently with the plasmid suspension. After 30 
min incubation at room temperature, transfection mix is diluted in 1 ml OPTI-MEM®I 
medium and put in a 35-mm dish onto 106 CV-1 cells infected with WT Vaccinia virus at 0.1 
m.o.i.. Lysed cells and medium are harvested 48 to 72 hours after infection: 1/104 of the viral 
solution is put onto 5x105 CV-1 cells in a 35-mm dish, for 1 hour at 37°C, and added with 2 
ml DMEM 10% FCS, Xanthine (2,6-Dihydroxypurine, C5H3N4NaO2, 174.09 D (Sigma 
Chemical co., St Louis, MO)), Hypoxanthine (6-Hydroxypurine, C5H4N4O, 136.11 D (Sigma 
Chemical co., St Louis, MO)), MPA (6-(4-Hydroxy-6-methoxy-7-methyl-3-oxo-5-
phthalanyl)-4-methyl-4-hexenoic acid, C17H20O6, 320.34 D (Fluka Chemie AG, Buchs, 
Switzerland)), for 2 days. Isolated plaques are selected under microscope and put in 1 ml 
PBS.  
This insertion of the plasmid is “secured” by 2 to 3 cycles under selective pressure. 
The second part of recombinant Vaccinia virus isolation consists of similar cycles of plaques 
isolation but without pressure, which lead to either excision of the entire plasmid (obtention 
of WT virus) or excision of the plasmidic part resulting in the obtention of recombinant virus 
(see figure 21).  
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2.4.3. Amplification and semi-purification of Vaccinia viruses 
 
Twelve 175 cm2 confluent flasks of CV-1 cells are infected with sonicated replicative 
virus at 0,01 m.o.i. leading to complete CPE. After 4 days culture, 8 ml TRIS 10mM are 
added on each decanted flasks. Infected cells are detached by 1 cycle of freeze-thaw, collected 
and centrifuged (2,500 x g, 4 min).  
Supernatant A is stored, while pellet is resuspended in 5 ml TRIS 10mM and sonicated 
to liberate viruses. After 4 minutes centrifugation at 2,500 x g, supernatant B is added to the 
selection 
Plasmid 
CD154 
gene 
Viral 
Promotor 
REC1 REC2 
VV 
WT 
CD154rV
V 
REVERSE 
REC1 
REC2 
REC1 
With pressure: UNSTABLE 
Figure 21. Principle of homologous recombination. 
 The expression/insertion cassette of the plasmid contains an early viral promoter as well as a 
Vaccinia virus early transcriptional termination sequence located downstream. This cassette is flanked by 
sequences being identical to different viral loci and allowing homologous recombination.  
 The gene of interest encoded by the plasmid is inserted by homologous recombination into the 
Wild Type strain (WT) of Copenhagen Vaccinia virus. This figure represents the first recombination 
possibility (beginning at REC1 site): the construction obtained by homologous recombination at the first 
site identical to a viral loci is unstable under selective pressure with mycophenolic acid (MPA), and can 
subsequently revert by recombination to the initial plasmid or to the plasmid encoding the CD154rVV by 
recombination at the second site (REC2). 
 The second recombination possibility (beginning at REC2 site) follows the same principle and 
ends to the plasmid encoding the CD154rVV by recombination at the first site (REC1) (not represented 
here). 
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viral solution A, while the pellet is resuspended in 3 ml of TRIS 10 mM, sonicated, and 
centrifuged (2,500 x g, 4 min). Supernatant containing the replicative viruses is added to the 
previous viral solution, distributed in Pollyallomer ultra-centrifuge tubes (1 x 3 ½ in. 
(Beckman Coulter, Fullerton, CA)), 25 ml per tube. 10 ml sucrose 36% underlayer cushions 
(β-D-Fructofuranosyl-α-D-glucopyranoside (=  D(+)-Saccharose = α-D-Glc-(1→2)-β-D-
Fru), C12H22O11, 342.30 D (Fluka Chemie AG, Buchs, Switzerland)) are added in each tube. 
After 1 h 30 min ultra-centrifugation at 30, 000 x g, pellets are resuspended in TRIS 1 mM, 
sonicated, aliquoted and stored at –20°C. 
 
2.4.4. Virus titration 
 
CV-1 cells are cultured in a 6 wells plate and grown to subconfluency. Replicative 
viral stock solutions are thaw, sonicated 1 min, and diluted in PBS from 10-1 to 10-8. After 
culture medium removal, 100 µl of the 10-6 to 10-8 dilutions are added to the wells. Virus 
adsorption to cells occurs during 1 hour incubation at 37°C. The plate is regularly slowly 
shaken every 10 minutes to avoid cells drying. 2 ml of medium are added in each well and the 
cells are incubated for 24 to 48 hours. Medium is aspirated, cells stained 1 min by 500 µl of 
0.1% violet crystal (Hexamethylpararosaniline chloride, C25H30ClN3, 407.98 D (Fluka 
Chemie AG, Buchs, Switzerland)) diluted in ethanol, and the plaques are counted under light. 
The viral stock solution concentration is calculated following the formular: viral 
concentration (pfu/ml) = number of plaques x 10 x dilution factor. 
 
2.4.5. Vaccinia virus inactivation by psoralen and long-wave UV light 
 
Vaccinia virus is diluted to a concentration of 5x108 PFU/ml in a Hanks’ Balanced 
Salts Solution (Invitrogen, Carlsbad, CA) containing 3 µg/ml Psoralen (CN Biosciences, 
Nottingham, UK). After 10 min incubation at room temperature, 1 ml of the solution is 
irradiated in an uncovered 35-mm dish with 365 nm UV light for 16 min, applied energy 1.6 J 
(Stratalinker, Stratagene, La Jolla, CA) and aliquoted in 250 µl vials.  
In order to rapidely evaluate the extent of the inactivation, CV-1 cells are infected with 
PLUV virus at different m.o.i. (from 0 to 20). Cytopathic effect (CPE) is evaluated under 
microscope after 24 hours infection. The shape of the non infected cells monolayer referres to 
0% CPE. The global changes in the morphology of the culture determinates the percentage of 
CPE. 100% CPE correspond to 100% cell displaying cytopathic morphology. 
 
2.5. Gene expression analysis 
 
2.5.1. Total RNA isolation  
 
Cells (1x107 maximum) are lysed in denaturating guanidine isothiocyanate (GITC)-
containing buffer inactivating RNases. Ethanol is added to provide appropriate binding 
conditions, and the sample is applied to RNeasy® mini column (Qiagen, Basel, Switzerland). 
RNA molecules > 200 nucleotides bind to the silica membrane, providing an enrichment for 
mRNA since most RNAs < 200 nucleotides (such as 5.8S rRNA, 5S rRNA and tRNAs).  
Technically, cells are washed in PBS, pelleted, and lysed by 350 µl of RLT buffer 
containing 1% β-mercapto-ethanol. 350 µl of ethanol 70% are added and 700 µl of the sample 
are applied on the column. After centrifugation (8,000 x g, 15 sec), the column is washed with 
700 µl RW1 buffer, and twice with 500 µl RPE buffer. The silica membrane is dried by 
centrifugation (2 min at 8,000 x g). The column is transferred to a collection tube and RNAs 
are eluted in 50 µl RNase-free water by centrifugation (8,000 x g, 1 min). 
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2.5.2. DNA digestion  
 
1µg RNA is incubated with 1 unit DNase I (Deoxyribonuclease I, Amplification Grade 
(Invitrogen, Carlsbad, CA)) with the buffer from supplier, for 15 min at room temperature. 
DNase I is then inactivated by 1 µl of  EDTA 25mM and by heating for 10 min at 65°C. 
 
2.5.3. RNA Reverse Transcription  
 
Moloney Murine Leukemia Virus Reverse Transcriptase (M-MLV RT, Invitrogen, 
Carlsbad, CA) uses single-stranded RNA in the presence of a primer to synthesize a 
complementary DNA strand up to 7 kb.  
Technically, 1 µg of RNA (11 µl) is incubated 5 min at 65°C with 1 µl oligo(dT)20 
primer at 50 µM (Invitrogen, Carlsbad, CA) at 500 µg/ml or 1 µl random hexamers at 0.09 
OD260 units/ml (Invitrogen, Carlsbad, CA). This mix is quickly chill on ice. Reverse 
transcription is performed with 4 µl buffer from supplier, 1 µl dNTP Mix (10 mM each dATP, 
dGTP, dCTP and dTTP), 2 µl DTT 0.1 M (C4H10O2S2, 154.24 g/mol (Invitrogen, Carlsbad, 
CA)), and 1 µl (200 units) of M-MLV RT, by 1 hour incubation at 37°C. Enzyme is 
inactivated by 5 min heating at 95°C. 
 
2.5.4. Gene expression by Real-Time qPCR 
 
Real-time PCR reactions are performed in the presence of three sequence-specific 
oligonucleotides. Two of them serve as conventional PCR primers for the amplification of 
target molecules. The third fluolabeled oligonucleotide (probe) hybridizes within the 
amplified region: this probe is labeled with a reporter and a quencher dye in a distance of a 
few base pairs within the probe sequence. The reporter fluorescent dyes FAM (6-carboxy-
fluorescein phosphoramidite, emission λmax = 518 nm) and the quencher dye molecule 
TAMRA (5-carboxy-tetramethyl-rhodamine, emission λmax = 582 nm) are incorporated at 
nucleotide nine of the 5’ and 3’ end of the oligonucleotide, respectively. In close steric 
proximity FAM works as a reporter while TAMRA is a quencher, greatly reducing the 
fluorescence emitted by the reporter dye. The 3’ nucleotide of this oligonucleotide is blocked 
by phosphorylation, preventing elongation by Taq DNA polymerase. During PCR 
amplification, DNA polymerase extends the primers and displaces the probe from the 
template, hydrolyzing it through its 5’-exonuclease activity. Thus, reporter and quencher dyes 
are separated leading to a measurable increase of fluorescence. This emitted fluorescence is 
directly proportional to the number of template molecules in the tube. Threshold cycle (Ct) 
refers to the cycle when fluorescence signal exceeds the mean of background fluorescence 
plus ten times the standard deviation in cycle 3 to 15.  
Quantification of cytokine gene expression was calculated by using the 2-∆∆CT method. 
This method uses a reference sample for comparison of every unknown sample’s gene 
expression and gives similar results as the standard curve method (Livak et al., 2001; Malec et 
al., 2004; Nieman et al., 2004; Winer et al., 1999). Briefly, ∆CT [CT (gene of interest) – CT 
(reference gene GAPDH)] is calculated for each sample and reference sample (condition 
infected with CD154rVV at lowest m.o.i.). ∆∆CT [∆CT (reference sample) – ∆CT (sample)] is 
evaluated, and relative quantification is calculated as 2-∆∆CT. The results are expressed as a n-
fold difference relative to the reference sample. A one-unit change in CT reflects a two-fold 
change in mRNA content. Verification of equally purified and equally infected samples was 
performed respectively with vvI3L, a viral early gene (Rochester et al., 1998), and 18S genes.  
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Practically, Real-Time qPCR are performed in Thermofast® 96 wells plate (Abgene, 
Epsom, UK), using the TaqMan® Universal PCR Master Mix, No AmpErase® UNG 
(Applied Biosystems, Forster City, CA) and the ABI prim™ 7700 sequence detection system 
(Applied Biosystems, Forster City, CA). Stage 1 consists in 2 min at 50°C followed by stage 
2: 10 min at 95°C. Stage 3 is repeated 45 times consisting in 15 sec at 95°C followed by 1 
min at 60°C. Datas are collected at these two steps of stage 3 and analyzed. Normalization of 
sample was performed using GAPDH as reference gene.  
 
2.6.  IL-12p70 detection by Enzyme Linked Immuno-Sorbent  Assay (ELISA)  
 
IL-12p70 ELISA is performed using Human IL-12(p70) BD OptEIA™ ELISA Set 
(Becton Dickinson, Franklin Lakes, NJ).  
Serial dilutions of standard protein (500 pg/ml) is performed in Assay Diluent 
(NalgeNunc International, Rochester, NY) to 250, 125, 62.5, 31.3, 15.6, 7.8 and 0 pg/ml.  
A 96 wells plate (Nunc-Immuno™ 96 MicroWell™ Plates (NalgeNunc International, 
Rochester, NY)) is coated with 100 µl per well of Capture Antibody 1:250 diluted in Coating 
Buffer 0.1 M (pH 9.5, 8.40 g NaHCO3, 3.56 g Na2CO3; q.s. to 1.0 l), sealed (Nunc Sealing 
polyester Tapes for ELISA plates (NalgeNunc International, Rochester, NY)) and incubated 
overnight at 4°C. Plate is washed 3 times with wash buffer (PBS with 0.05% Tween®20 
(Sigma Chemical co., St Louis, MO)), blocked with 200 µl/well Assay Diluent, incubated 1 
hour at room temperature, and washed 3 times more. Samples are diluted in Assay Diluent. 
100 µl of each standard, sample, and control are put in duplicate in the plate. The plate is 
sealed and incubated for 2 hours at room temperature. Plate is washed 6 times. 100 µl of 
1:250 diluted Detection Antibody (Biotinylated Anti-human IL-12(p70), is added to each 
well, the plate is sealed, incubated for 1 hours at room temperature, and washed 6 times.  
To each well, 100 µl of 1:250 diluted Enzyme Reagent (Avidin-horseradish 
peroxidase conjugate) is added, the sealed plate is incubated 30 min at room temperature, and 
washed 6 times. 100 µl of substrate (BD Pharmingen™ TMB Substrate Reagent Set: 
Tetramethylbenzidine (TMB) and Hydrogen Peroxide (Becton Dickinson, Franklin Lakes, 
NJ)) is added to each well for 5 to 30 min incubation in the dark. The enzymatic reaction is 
stopped by 50 µl of Stop Solution (2N H2SO4). Absorbance is read at 450 nm within 30 min 
of stopping reaction.  
 
2.7. Phenotypic characterization of cells 
 
2.7.1. Flow cytometry analysis 
 
CD154 expression after cell infection was verified using anti-CD154 PE-conjugated 
antibodies (Immunotech, coulter company, Marseille, France). Infected cells were stained 
with specific or control IgG antibodies, incubated 45 min at 4°C in the dark, washed twice in 
cold PBS, fixed 1 min in Parafolmaldehyde 1% (Polyoxymethylene, [CH2O]n, 30.03 D, 
(Fluka Chemie AG, Buchs, Switzerland)), re-suspended in 200 µl PBS, and analyzed on a 
FACSCalibur® cytometer (Becton Dickinson, Franklin Lakes, NJ). 
 Staining with antibodies for CD83, CD14, CD1a, CD80, CD86 (PE or FITC-
conjugated antibodies - PharMingen, San Diego, CA), were performed following the same 
protocol. 
 
2.7.2. Tetramer analysis for direct visualization of CD8+ T cells  
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Peptide-MHC, ligand for a given population of T cells bearing TCRs with a 
corresponding specificity, are multimerized in soluble peptide-MHC tetramers: only the T 
cells that have TCR capable of binding to the particular MHC-peptide combination of the 
tetramer are able to bind the tetramer (Altman et al., 1996). The concomittent use of a 
monoclonal antibody that is specific for a T cell marker and conjugated with fluorescein 
isothiocyanate, for instance anti-CD8 monoclonal antibody FITC-conjugated, allows the 
detection of CD8+ T cell specific for the peptide of interest (see figure 22). 
MART-1/Melan-A27-35 specific Tetramer (ProImmune, Oxford, UK - 1/100 diluted) 
followed by anti-CD8+ FITC-conjugated antibodies (PharMingen, San Diego, CA - 1/100 
diluted) were used to identify MART-1/Melan-A27-35 specific CD8+ T cells. 
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Figure 22. Tetramer analysis to detect peptide specific T cells. 
(a) Soluble heavy chain of major histocompatibility complex (MHC) class I molecules are synthesized 
in Escherichia coli. (b) The molecules adopt an appropriate conformation following the addition of β2 
microglobulin (β2m) and a synthetic peptide that represents the epitope that is recognized by the T-cell 
receptor of interest. This peptide is able to bind to the MHC molecule. In addition, the enzyme BirA is 
used to atach a biotin molecule to the specific BirA-recognition sequence, which has been incorporated 
into the carboxyl terminus of the MHC molecule. (c) Four MHC-biotin complexes are linked to a 
single streptavidin molecule, using the specific biotin-streptavidin interaction, to form a tetramer. The 
straptavidin molecule is tagged with a fluorochrome (e.g. phycoerythrin; PE). (d) Tetramers are mixed 
with the cell population that is to be analyzed. Only T cells that are capable of binding to the particular 
MHC-peptide combination that is present in the tetramer are able to bind the tetramer; thus, such cells 
will become labelled with the PE fluorochrome. A monoclonal antibody that is specific  for a T-cell 
marker and is tagged with a different fluorochrome (e.g. fluorescein isothiocyanate (FITC)), can also 
be used. (e) The cells are then analyzed using flow cytometry; the proportion of the CD8+ T-cell 
population that stains positively with the tetramer can be determinated (top, right-hand quandrant). 
 Largely inspired from: Expert Reviews in Molecular Medicine, www-ermm.cbcu.cam.ac.uk, 
accession number: fig004jhc. 
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2.7.3. Cell apoptosis quantification by PI/annexin staining (Annexin V-FITC 
Apoptosis Detection Kit I (BD Pharmingen™, Franklin Lakes, NJ)) 
 
In apoptotic cells, phosphatidylserine (PS) is translocated from the inner to the outer 
leaflet of the plasma membrane, and is thereby exposed to the external cellular environment. 
Annexin V is a Ca2+ dependent phospholipid-binding protein that has a high affinity for PS 
(Raynal et al., 1994). Since externalization of PS occurs in the earlier stages of apoptosis, 
Annexin V staining can identify apoptosis at an early stage. Annexin V is typically used in 
conjunction with Propidium Iodide (PI), which is a vital dye excluded in viable cells with 
intact membrane. For example, viable cells are Annexin V and PI negative, early apoptotic 
cells are Annexin V positive and PI negative, and late apoptotic or dead cells are both 
Annexin V and PI positive. 
Technically, the cells are washed twice with cold PBS and then resuspend in 1X 
binding buffer at a concentration of 1 x 106 cells/ml. 100 µl of this solution (1 x 105 cells) is 
transferred to a 5 ml culture tube, and 5 µl of Annexin V and 5 µl of PI are added. Cells are 
gently vortexed and incubated for 15 min at room temperature in the dark. 400 µl of 1X 
binding buffer are added and cells are analyzed by flow cytometry within one hour. 
 
2.8. Induction of antigen-specific CTL by stimulation with CD154rVV of APCs 
from healthy donors 
 
We tested the capacity of CD154rVV to enhance induction of  MART-1/Melan-A27-35-
specific CTL in culture of infected APCs with autologous CD8+ T Cells. APC from healthy 
donors, CD14+ cells or iDC, were infected at different m.o.i. with CD154rVV or wild-type 
VV and co-cultured with autologous CD8+ T cells, as compare to APC cocultured with CD8+ 
T cells with MART-1/Melan-A27-35 peptide (AAGIGILTV) at 10 µg/ml as antigen. After 1 
hour adsorption, infected cells were washed and cultured at 37°C in complete medium with 
the autologous CD8+ T cells. After 8 days, half of the medium was replaced with fresh 
medium containing a final concentration of 10 units/ml IL-2. In order to minimize the 
induction of vaccine-virus-specific CTL and to optimally expand TAA-specific CTL, 
lymphocytes were restimulated on day 12 or 13, and 19 using 20 µg/ml peptide-pulsed and 
irradiated autologous EBV-BL re-suspended in complete medium supplemented with 10 
units/ml IL-2. After supplementation of fresh medium and 10 units/ml IL-2 at day 22, 
cytotoxic activity was tested on day 26 of culture. MART-1/Melan-A27-35-specific CTL 
phenotype was characterized by tetramer straining before boosts and cytotoxicity assay. 
Similar experiments were performed using as antigenic peptide: EBV LMP2 
(CLGGLLTMV), EBV BMLF1 (GLCTLVAML) or CMVpp65 (NLVPMVATV) peptide. 
 
 
2.9.  Measure of cell-mediated cytotoxicity using 51Cr-release assay in vitro 
 
Chromium-release assay is a standard assay to measure in vitro cytotoxic function 
(Brunner et al., 1968). Target cells radiolabeled with sodium chromate (Na251CrO4) which is 
taken up by live cells in its hexavalent form, are incubated with the test effector-cell 
population for a short period of 4 hours. The amount of 51Cr released into the supernatant in 
its trivalent form is quantified to provide a measure of target cell lysis. 
Technically, appropriate target cells, for instance EBV-BL, are washed in CM 10% 
FCS and the pelleted cells are labeled with 400 µCi sodium 51-chromate (Na251CrO4, half-life 
27.7 days, (Amersham Biosciences, Buckinghamshire, UK)) in solution per 107 targets. 
  
 
57 
Targets are labeled for 1 hour in a 37°C, 5% CO2, humidified incubator, with occasional 
shaking to inhibit pelleting. These targets are then washed two times in PBS and resuspended 
in 2 ml CM 10% FCS. Cells suspension is adjust to 2.5 x 104 / ml in CM 10% FCS. Effector 
cells, meaning CTLs are resuspended in 2 ml CM 10% FCS, and then adjust to their final 
plating concentration. Effector cells are added in the first raw of a 96 wells plate, and diluted 
1:2 in the following wells in order to evaluate cytotoxicty at different Effector / Target ratio 
(E/T). 100 µl of target labeled cells are added in each well. Addition of a fixed number of 
target labeled cells on effector cells at multiple ratio achieves to various E/T ratio. The 
spontaneous release is measured in the wells containing only labeled target cells. The 
maximal release is obtained by complete lysis of labeled-target cells by HCl 1M addition. The 
plate is centrifuged 5 min at 150 x g , incubated at 37 °C for 4 hours.  
Plate is then centrifuged and 30 µl of supernatants from each well are transferred into 
a lumaplate (Perkin-Elmer, Boston, MA). Release radioactivity is measured in a gamma-
counter. Data are expressed as percentage of specific lysis of target cells ([(sample count – 
spontaneous count) x 100] / [maximal count – spontaneous count]). 
 
2.10.  Cell proliferation assays using 3H-Thymidine incorporation 
 
T lymphocytes proliferation was measured by incorporation of tritiated thymidine (3H-
Thy) into the DNA of dividing cells, providing a measure of the rate of DNA synthesis by the 
entire cells population. 
CD14+ cells and T lymphocytes are cocultured in a 96 wells plate with flat bottom, in 
a final volume of 200 µl per wells. Cultured stimulated with PHA (4 µg/ml) are used as 
positive control. After 4 or 5 days incubation at 37°C, 3H-Thy (20 µl of a 1/20 dilution)  is 
added per well and reincubated for 18 hours. Cells are harvested and lyzed by an osmotic 
choc in a  Micro96™ Cell Harvester (Skatron, Sunnyvale, CA). Nucleic acids are sticking on 
a prewetted glass fiber filter (Printed FiltermatA, Wallac, Turku, Finland). After 3 washes, the 
filter is dried, and enclosed in a plastic bag (Sample Bag, Wallac, Turku, Finland). Liquid 
scintillation cocktail is added (OPTI-FLUOR®, PerkinElmer, Boston, MA) and scintillation 
emission is measured. 
 
2.11. Lymphoproliferation assays using CFSE staining 
 
The principle is summarized in figure 23 (Parish, 1999). Technically, lymphocytes are 
pelleted and washed once with PBS to remove all contaminating free proteins. The cells are 
resuspended in 1 ml PBS. 3 µl CFSE (5-(and-6)-carboxyfluorescein diacetate, succinimidyl 
ester (5(6)-CFDA, SE;CFSE) mixed isomers, C29H19NO11, 557.47 D (Molecular Probes, 
Eugene, OR)), stock at 5 mM are diluted to 1/2500 by addition of 7.5 ml PBS. 1 ml 
CFSE1/2500 is added to 106 cells (in 1 ml PBS). CFSE dilution is finally 1/5000 (0.001 mM). 
Cells are incubated 10 min at 37°C in a water bath, and at least the same volume of blocking 
solution (complete medium) is added in order to block unbound CFSE. Cells are pelleted by 
centrifugation (5 min, 800 x g), washed 3 times with PBS, and finally resuspended in CM 
10% AB medium for 5 days culture. Lymphocytes proliferation is evaluated by FACS 
analyses: at each cell division, the amount of CFSE initially present in the cells is divided by 
two between the daughter cells. 
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Figure 23. Principle of lymphoproliferative measurement using CFSE. 
The non-fluorescent, highly membrane permeant, 5-(and-6)-carboxyfluorescein diacetate, 
succinimidyl ester (CFDASE) is readily taken up by cells, although its high lipophilicity also allows it 
to freely exit from cells. Intracellular esterases, however, can remove the two acetate groups from 
CFDASE to yield fluorescent 5-(and-6)-carboxyfluorescein succinimidyl ester (CFSE), which is much 
less membrane permeant and, therefore, exits from cells at a much slower rate. The succinimidyl 
moiety of CFSE is highly reactive with amino groups and can covalently couple 5-(and-6)-
carboxyfluorescein (CF) to intracellular molecules. In some cases, CF covalently couples to 
intracellular molecules (R1-NH2) to form conjugates (CFR1) that can still exit from the cell or are 
rapidly degraded. However, a proportion of CF becomes coupled to long-lived intracellular molecules 
(R2-NH2) to form conjugates (CR2) that can not escape from the cell and thus, stable fluorescent 
labeling of cells is achieved. The principle is summarized in figure 6 (Parish CR et al., 1999).  
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 RESULTS 
 
1. CD154rVV construction 
 
A two-step procedure has been developed to construct recombinant Vaccinia viruses. 
In the first step, a plasmid containing a foreign gene controlled by a Vaccinia virus promoter 
and flanked by sequences derived from a non essential site on the viral genome is generated. 
In the second step, the foreign genetic material of the plasmid vector is inserted into the viral 
genome by homologous recombination in vivo (Falkner et al., 1988). Principle of this 
technology (Hruby, 1990) is summarized in Figure 24. 
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Figure 24. Principle of recombinant Vaccinia virus construction. 
A foreign gene controlled by VV promoter and flanked by sequences derived from non essential site 
on the viral genome is encoded by a plasmid, and inserted into the viral genome by homologous 
recombination in vivo. Recombinant Vaccinia virus are selected, purified, grown and the presence of 
the transgene is verified by genomic, transcriptional and functional analysis. 
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Human PBMC from an healthy donor were stimulated by PHA (5 µg/ml) and IL-2 (10 
U/ml) for 24 and 48 hours. Cells were collected, washed and total RNAs were extracted. After 
DNase treatment and Reverse Transcription, CD154 cDNA was PCR amplified (Photo 1). 
1,018 bp 
1,636 bp 
2,036 bp 
3,054 bp 
792 bp 
24h 48h ladder 
Photo 1: CD154 cDNA PCR amplification. 
Human PBMC from a healthy donor were stimulated with PHA (5 µg/ml) and 
IL-2 (10 units/ml) for 24 and 48 hours. After RNA extraction, DNase treatment 
and Reverse Transcription, CD154 cDNA was PCR amplified and the expected 
792 bp bands corresponding to the CD154 cDNA were cut out for the next 
steps. 
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CD154 cDNA was inserted by BamHI-EcoRI restriction into pKT1323 (generous gift 
from Dr. K. Tsung (San Francisco, CA)), between a Vaccinia virus early promoter and an 
early transcriptional termination sequence (Davison et al., 1989a). Escherichia coli guanine 
phosphoribosyl transferase (gpt) gene was used as a transient marker for selection of 
recombinant Vaccinia virus (Falkner et al., 1990). The plasmid was transformed in E. coli by 
electroporation. 
Restriction analysis of 4 clones was performed by using either BamHI + EcoRI or 
PvuII (5’ CAG  CTG 3’,  (Invitrogen, Carlsbad, CA)) restriction enzymes. 
 
 
 
 
 
 
 
Selected clones were analyzed by restriction profile and sequencing confirmed the 
presence of CD154 insert. Nevertheless, the natural sequence of CD154 contains two 
TTTTTNT sequences, which are known to be STOP sequences for Vaccinia virus early 
transcription (Yuen et al., 1987). Point mutations in the these sequences may result in 
production of full-length early mRNAs in the absence of modifications of the amino acids 
sequence (Earl et al., 1990). Therefore, to maintain the expression of the entire CD154 
protein, mutation of the two nucleotides sequences were performed as described below. 
This basic procedure used for mutagenesis in plasmid sequence utilizes two synthetic 
oligonucleotide primers containing the desired mutations. In our case, as the two mutation 
points were close, we could design oligonucleotides with both desired mutations as shown 
below: 
 
CD154-mutFor: 
5’-GCA TGA AAA TAT TTA T GT ATT TAC TTA CTG TGT TTC TTA TCA C-3’ 
 
Nucleotide 1309: A instead of T 
 
T was replaced by A because it conserved the resulting amino acid (Ile) and created a 
SspI site (5’AAT│ATT3’). 
 
BamHI 1235 
EcoRI 2027 
PvuII 1718 
PvuII 3664 
pKT1323-CD154 
5722 bp 
C
D
1 
5 
4 
pKT1323 
4944 bp 
BamHI 1235 
EcoRI 1249 
Ile 
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CD154-mutRev: 
5’-GTG ATA AGA AAC A CA GTA AGT AAA TAC ATA AAT ATT TTC ATG C-3’ 
 
Nucleotide 1330: C instead of A ( which conserves the resulting amino acid (Val)). 
 
Summarize: 
 
5’-AGC ATG AAA ATA TTT  ATG TAT  TTA CTT  ACT  GTG  TTT  CTT ATC ACC CAG-3’ 
3’-TCG TAC TTT   TAT AAA TAC ATA AAT GAA TGA  CAC AAA GAA TAG TGG GTC-5’ 
 
To generate a recombinant Vaccinia virus expressing CD154 (CD154rVV), the 
CD154 gene encoded by the mutated plasmid was inserted by homologous recombination into 
the Copenhagen Wild Type strain (WT) of Vaccinia virus (generous gift from Dr. R. Drillien, 
Strasbourg, France). Recombinant viral clones were selected according to their transient 
expression of the E. coli gpt marker, by several cycles of “plaque picking” under the selective 
pressure of MPA, xanthine and hypoxanthine (described in materials and methods). 
Additional selection rounds without pressure enable to eliminate the selection marker. 
Isolated plaques were amplified on confluent CV-1 cells and PCR tested to verify insertion. 
CD154rVV was then semi-purified from these cultures of infected CV-1 cells, on a 36% 
sucrose cushion. The resulting concentrated viral suspension was titrated (see one example of 
VV titration on Photo 2), and finally rendered replication incompetent by psoralen and long-
wave UV treatment.  
 
 
 
 
 
 
2. CD154 expression 
 
2.1. CD154 protein expression on CD154rVV infected CV-1 cells 
 
The capacity of the recombinant Vaccinia virus to express CD154 recombinant protein 
was verified by infecting constitutively CD154 negative CV-1 cells and using as controls non 
infected or Wild Type (Control VV) infected cells. Infections were performed either with 
Val 
CD154mutFor 
CD154mutRev 
Photo 2. CD154rVV titration. 
Confluent CV-1 cells cultured in 6 wells plates, were infected with 
100 µl replicative virus 10-6 or 10-7 or 10-8 diluted, and cells were 
stained after 24 hours infection, to visualize plaque forming units 
(pfu) induced by the replication of virus. As replicative Vaccinia 
virus life cycle ends by the lysis of infected cells, one initial virus will 
induce after replication the formation of a hole visible in the cell 
monolayer. For staining, medium was removed and cells were stained 
with 0.1% violet crystal. 
Viral concentration (pfu/ml) = number of pfu x 10 x dilution factor 
Here, viral concentration = 123 x 10 x 106 pfu/ml 
  
 
65 
replicative virus at 5 m.o.i. or with replication-incompetent (psoralen long-wave UV 
inactivated: PLUV) virus at 20 m.o.i.. Cell surface expression of CD154 was verified by 
staining with an antibody specific for human CD154 and analyzed by flow cytometry.  
As shown in figure 25, CD154 is indeed expressed on the surface of all CV-1 cells 
infected with replicative CD154rVV, whereas non infected cells and CV-1 cells infected with 
the replicative Control VV do not display CD154 expression. Similarly, CV-1 cells infected 
with PLUV inactivated CD154rVV express the recombinant CD154 protein while PLUV 
Control VV infected and non infected cells do not, thus demonstrating that expression of the 
transgene can be observed in high percentages of infected cells, although the psoralen long-
wave UV treatment is affecting long gene expression (Tsung et al., 1996).  
Figure 25. Flow cytometric analysis of the cell surface expression of CD154 in 
CD154rVV infected cells.  
CV-1 cells (constitutively CD154 negative) were infected either with the replication-
incompetent CD154rVV (PLUV) or with PLUV control VV at m.o.i. 20, or with the 
replicative CD154rVV or control VV at 5 m.o.i., and cultured overnight. Cells were 
stained with either PE-labeled anti-CD154 mAbs (thick line) or with Isotype control 
antibodies (thin line), washed, fixed with paraformaldehyde 1%, and subsequently 
analyzed by flow cytometry. Non infected (NI) CV-1 cells were used as negative 
control. 
NI CD154rVV 20 m.o.i. Control VV 20 m.o.i. 
Replicative 
Control VV 5 m.o.i. 
Replicative 
CD154rVV 5 m.o.i. 
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We also confirmed the relation between the dose of inactivated virus and the number 
of cells expressing the recombinant protein on their surface. As shown in figure 26, infection 
at a viral dose of 5 m.o.i. of CV-1 cells with PLUV CD154rVV, results in two populations, 
one clearly negative regarding CD154, and another one expressing the recombinant protein 
following to infection. With a higher viral dose (10 m.o.i.), the number of cells positive 
increases and reaches almost 100% of efficiently infected cells above 20 m.o.i.. 
Figure 26. CD154 cell surface expression in CD154rVV infected cells as function of  viral doses.  
CV-1 cells were infected either with the replication-incompetent CD154rVV (PLUV) at 5, 10 or 20 
m.o.i., and cultured overnight. Cells were stained with either PE-labeled anti-CD154 mAbs (thick line) 
or with Isotype control antibodies (thin line), washed, fixed with paraformaldehyde 1%, and 
subsequently analyzed by flow cytometry. Non infected (NI) CV-1 cells were used as negative control. 
CD154rVV 20 m.o.i. 
CD154rVV 10 m.o.i. 
CD154rVV 5 m.o.i. 
NI 
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2.2. CD154 gene expression in CD154rVV infected monocytes upon 36 h infection 
 
Following T cell receptor triggering on CD4+ T cells in vitro, CD154 surface 
expression is maximal from 8 hours following activation. Subsequently, the surface 
expression of CD154 is rapidly downregulated to background level within 24 hours following 
stimulation (Yellin et al., 1994b). In contrast, it is known that foreign gene expression induced 
by recombinant Vaccinia virus rendered replication-incompetent by psoralen and long-wave 
UV treatment, is sustained and still effective for at least three days after infection (Tsung et 
al., 1996). Because T cells are not susceptible to Vaccinia virus infection, we therefore 
comparatively verified the level of CD154 gene expression in infected CD14+ cells upon 36 
hours infection, and in CD4+ T cells stimulated by culture with infected monocytes.  
Figure 27 is displaying CD154 gene expression in infected monocytes and in total 
PBMC, upon 36 hours infection. CD4+ T cells cultured with autologous non infected PBMC 
are used to quantify the background level of CD154 gene expression in CD4+ T cells after 36 
hours in vitro culture without any stimulation. As complementary control, we quantified 
CD154 gene expression in CD4+ T cells stimulated by culture with autologous PBMC, 
including monocytes infected with PLUV control VV. As expected, PLUV CD154rVV 
infected but not non infected and control VV infected monocytes, are expressing the CD154 
recombinant gene, to a dramatically higher level (47.83 times more at m.o.i. 10) than the 
CD154 background level expressed in CD4+ T cells after 36 hours culture without any 
stimulation. These dose-dependent results are also observed in total PBMC including infected 
CD14+ cells, even if CD154 gene expression level is lower because of CD14+ cells dilution 
in total PBMC. On the other hand, CD4+ T cells cultured with total PBMC including control 
VV infected monocytes only displayed marginal CD154 gene expression upon 36 hours 
culture, since CD154 gene expression is similar to the background level of CD4+ T cells 
cultured without any stimulation.  
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Figure 27. CD154 gene expression in PBMC upon CD14+ infection. 
4x106 CD14+ cells were infected with the replication-incompetent (PLUV) CD154rVV or 
Control virus at 1, 5 or 10 m.o.i. and cultured with 10x106 CD14-. Non Infected (NI) CD14+ 
and cells cultured with LPS (1 µg/ml) were used as controls. CD4+ and CD14+ cells were 
sorted after 36 hours co-culture using microbeads, and CD154 gene expression was analyzed 
by quantitative real-time PCR in (A.) CD4+ sorted cells cultured with infected CD14+ cells 
and the rest of the CD14- cells fraction, (B.) infected CD14+ cells alone and (C.) in total 
PBMC including infected CD14+. Data are expressed as fold increase as compared to CD154 
expression in CD4+ cells culture with total non infected PBMC.  
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These results confirm that CD154rVV is expressing CD154 gene in infected cells, and 
that this expression is still significantly higher 36 hours after infection in infected monocytes 
than in stimulated CD4+ T cells. This prolonged CD154 expression may be an advantage in 
our context: the longer the monocytes are expressing CD154 upon CD154rVV infection, the 
longer this molecule should have a potential effect on APC activation by “cross self-
stimulation” and T cell priming. 
 
2.3. CD154 gene expression as activation marker for T cell stimulated by CD154rVV 
infected monocytes 
 
Following T cell receptor triggering of CD4+ T cells in vitro, CD154 surface 
expression is maximal from 8 hours following activation and rapidely decreases to a 
background level. To verify if recombinant CD154 expressed by CD154rVV infected 
monocytes could, eventually, prolong CD4+ T cells activation, we also monitored CD154 
gene expression in T cells following 36 hours culture with infected monocyte (Figure 28). 
Infected CD14+ cells fraction from PBMC were cultured with autologous CD14- cells 
fraction. After 36 hours culture, CD4+ and CD8+ T cells were sorted using micro-beads, and 
CD154 gene expression subsequently analyzed. CD4+ T cells cultured with autologous non 
infected PBMC were used to quantify the background level of CD154 gene expression after 
36 hours in vitro culture without any stimulation.  
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Figure 28. CD154 gene expression on T cells induced by culture with infected CD14+. 
4x106 CD14+ cells were infected with the replication-incompetent (PLUV) CD154rVV or Control virus 
at 1, 5 or 10 m.o.i. and cultured with 10x106 CD14-. Non Infected (NI) CD14+ and cells cultured with 
LPS (1 µg/ml) were used as controls. CD4+ and CD8+ cells were sorted after 36 hours co-culture using 
microbeads technology, and CD154 gene expression was analyzed by quantitative real-time PCR in (A.) 
CD4+ and (B.) CD8+ cells cultured with infected CD14+ cells and the rest of the CD14- cells fraction. 
Data are expressed as fold increase as compared to CD154 expression in CD4+ cells culture with total 
non infected PBMC.  
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Regarding CD4+ T cells activation upon 36 hours stimulation with infected 
monocytes, no major differences were observed in CD154 gene expression by CD4+ T cells 
cultured either with CD154rVV or Control VV infected monocytes. In addition, level of 
CD154 gene expression is similar to the one observed in non stimulated CD4+ T cells. It 
seems that recombinant CD154 expressed on CD154rVV infected monocytes is not 
prolonging CD4+ T cell activation to 36 hours, or at least, CD154 induction at their surface. 
Interestingly, CD8+ T cells cultured with CD154rVV infected CD14+ cells for 36 
hours, showed a marked CD154 gene expression induction as opposed to CD8+ T cells 
cultured with non infected or Control VV infected monocytes. It seems that CD154rVV 
infected monocytes are acting, for at least 36 hours, on CD8+ T cells, which respond by 
CD154 induction on their cell surface. 
 
3. Impact of CD154rVV on Antigen Presenting Cells 
 
3.1. Direct and indirect APC stimulation 
 
CD154rVV impact on Antigen Presenting Cells (APC) was evaluated in two different 
culture setting.  
Because T cells are not susceptible to Vaccinia virus infection, the first method 
consists in a direct APC infection: CD154 recombinant protein expressed on the surface of 
CD154rVV infected APC will bind to the CD40 expressed on the neighbouring APC. This 
binding results in APC stimulation, in a so called “cross self-stimulation”. 
However, intradermal injection of VV is likely to result in the massive infection of 
fibroblasts, present in a large numbers in these districts where comparatively few putative 
APC are present. Thus, we were also interested in indirect effects of fibroblasts infection on 
non infected APC. In this second setting, CD154 expressed on the surface of CD154rVV 
infected fibroblasts binds the CD40 expressed on APCs, resulting in an “indirect” APC 
stimulation. 
 
3.2.  Apoptosis induction upon PLUV Vaccinia virus infection 
 
Since we are using Vaccinia virus as vector, we have to deal with some apoptosis 
induction, even if we are using PLUV inactivated viruses. Because it is known that CD154 is 
able to inhibit APC apoptosis, we investigated whether the recombinant Vaccinia virus 
expressing CD154 is inducing less apoptosis as compared to Wild Type virus used as control. 
 We first evaluated the impact of PLUV CD154rVV on infected CD14+ cells, since in 
the majority of our experiments, we used monocytes to demonstrate the effects of this virus 
on APCs. As shown in figure 29, even if we are using PLUV inactivated virus as vector, the 
Control virus increases to some extent the background amount of apoptotic and dead 
monocytes, as compared to non infected cells. This amount is nevertheless dramatically lower 
than the one observed in the presence of replicative virus (data not shown). Nevertheless, we 
showed that at same m.o.i., CD154rVV is inducing slightly lower apoptosis and necrosis of 
infected CD14+ cells. Even if non significant, these small differences were observed in the 
majority of the experiments performed. 
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We then considered the impact of PLUV CD154rVV on iDC apoptosis. As shown in 
figure 30, iDC appear to be markedly more sensitive to infection than monocytes, since 
apoptotic and necrotic cells reached at 8 m.o.i. 59,69% of cells, as compared to 22,77% for 
CD14+ cells infected with the same virus at 10 m.o.i.. Consequently, we had to choose lower 
m.o.i. (<5) for the long-term experiments in which we were using only DC, to maintain a 
reasonable amount of infected cells alive. Nevertheless, as shown on this figure, similarly to 
infected CD14+, we demonstrated that PLUV CD154rVV was inducing slightly less 
apoptosis and cell death as compared to the control virus, especially at low m.o.i.. 
Figure 29. Inhibition of apoptosis and cell death in infected CD14+ cells. 
2 x 106 CD14+ cells were infected with the replication-incompetent (PLUV) CD154rVV or 
Control virus at 10 m.o.i. and cultured overnight. Non infected cells (NI) were used as control. 
Cells were stained with PI/Annexin V and the percentages of  (A.) apoptotic and (B.) necrotic 
cells were evaluated by flow cytometry.  
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Figure  30. Inhibition of apoptosis and cell death in infected iDC cells. 
5 x 105 iDC cells were infected with the replication-incompetent (PLUV) 
CD154rVV or control virus at 1, 4 or 8  m.o.i. and cultured overnight. Non 
infected cells (NI) were used as control. Cells were stained with PI/Annexin V and 
the percentages of  (A.) apoptotic and (B.) necrotic cells were evaluated by flow 
cytometry.  
  
 
74 
 
We also tried to evaluate the impact of PLUV CD154rVV on iDC comparing direct 
and indirect system in which non infected iDC were co-cultured with infected allogenic 
fibroblasts. As shown in figure 31, although background level of cell death in the absence of 
infection is, in this experiment, quite high (≈17 %), cell death following direct iDC infection 
was increased, as compared to non infected cells. Even if the difference is not significant, it 
seems that CD154rVV infected iDC die slightly less (25,94 %) than iDC infected with the 
Control virus (27,86 %). iDC death seems to decrease when cultured with infected fibroblasts 
as compared to the directly infected iDC (21,48 % with Control virus infected Vero versus 
27,86 % for directly infected iDC). Even if not significant, this effect was even slightly more 
beneficial in the condition infected with CD154rVV (13,35 % of dead iDC).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
In conclusion, in our conditions, even if repeated, APC apoptosis inhibition by CD154 
properties seems really weak, and not really significant. One explanation could be that 
apoptotic events begin immediatly within minutes after infection. Indeed, as shown in figure 
32, some iDC seem to die already 1 hour after infection, as compared to non infected iDC. On 
the other hand, the virus requires some hours to express proteins : CD154 ligand was 
detectable at the surface of PLUV CD154rVV infected cells only after 3 hours infection. 
Events induced by CD154/CD40 pathways may be simply later in time than apoptotic events, 
and subsequently too late to have a real significant beneficial effects on infected cells. 
Figure 31. Inhibition of iDC cell death when co-cultured with infected 
fibroblasts. 
6.5 x 105 iDC cells were either directly infected with the replication-incompetent 
(PLUV) CD154rVV or Control virus at 3 m.o.i., or non-infected and co-cultured 
with 1 x 105 infected Vero cells. Dead cells were stained with PI and percentages of 
dead cells were evaluated after overnight culture by flow cytometry.  
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Figure 32. CD154rVV infected iDC: kinetic of CD154 expression on cell surface and 
apoptosis beginning.  
5 x 105 human iDC from a healthy donor were infected with the replication-incompetent 
CD154rVV (PLUV) at m.o.i. 5. Non infected cells (NI) were used as negative control. (A.) 
Cells were stained with PI/Annexin V and the percentages of cells still alive were 
evaluated by flow cytometry. (B.) Non infected cells (thin line) and CD154rVV infected 
cells (thick line) were stained with PE-labeled anti-CD154 mAbs, washed, fixed with 
paraformaldehyde 1%, and subsequently analyzed by flow cytometry. 
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3.3. Induction of cytokines genes expression in APC 
 
3.3.1. Cytokines genes expression induction in directly infected monocytes 
 
The effects of CD154 expression in CD154rVV infected cells on CD40+ antigen 
presenting cells were then investigated in detail. Indeed, CD40 ligation by its receptor induces 
in APC the expression of cytokines and surface molecules favoring T helper 1 responses.  
IL-12 is a heterodimeric cytokine composed of two different disulfide-linked subunits, 
p35 and p40 (Kobayashi et al., 1989). Whereas the IL-12p35 subunit is constitutively 
expressed in most cell types and post-translationally regulated (D'Andrea et al., 1992), IL-
12p40 expression, is controlled at transcriptional level (Ma et al., 1996) and its up-regulation 
can be used as marker of CD154/CD40 activation (Cella et al., 1996).  
In the experiment shown in figure 33, peripheral blood CD14+ cells from healthy 
donors, were infected at 10 m.o.i. with CD154rVV or Control VV, and incubated in complete 
medium for 24 hours. Total cellular RNA was reverse transcribed and cytokines gene 
expression was quantified by real-time quantitative PCR (qRT-PCR).  
As shown in figure 33A, IL-12p40 transcription in monocytes was exclusively 
detected following CD154rVV infection. Furthermore, as shown in figure 33B and C, 
expression of GM-CSF and TNF-α genes was indeed also observed following infection with 
control virus (WT) but at significantly lower levels as compared to those observed upon 
CD154rVV infection.  
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Figure 33. Induction of cytokine genes expression in infected CD14+ cells. 
2 x 106 CD14+ cells were infected with the replication-incompetent (PLUV) CD154rVV or 
control virus at 10  m.o.i. and cultured overnight. Non infected cells (NI) were used as negative 
control. IL-12p40 (A.), GM-CSF (B.) and TNF-α  (C.) gene expression was analyzed by 
quantitative real-time PCR and data were expressed as ratio to CD154rVV infected samples. 
Symbols (∗) indicate values significantly (p< 0.05) different as compared to control VV 
infected cultures. 
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IL-6 is a pro-inflammatory cytokine induced during infection (Reviewed in (Hopkins, 
2003)). CD154 is known to induce IL-6 secretion by monocytes and dendritic cells (Sugiura 
et al., 2000; Wesa et al., 2002). This increase in IL-6 secretion may promote IgG secretion 
accompanied by antibody isotype switching (Urashima et al., 1996). In addition, IL-6 has 
been shown to render pathogen-specific T cells refractory to the suppressive activity of CD4+ 
CD25+ T regulatory cells (Pasare et al., 2003). We hypothesized that the effect of CD154rVV 
on CTL activation could also benefit from an increase in IL-6 induction. 
However, as shown in figure 34, probably due to the already strong effect of the virus 
itself, no significant differences were obtained between CD154rVV and Control virus 
regarding IL-6 gene expression induction, neither in infected CD14+ or PBMC, nor in CD4+ 
or CD8+ cells cultured with autologous infected CD14+ cells. Similarly, no differences were 
observed in infected CD14+ cells cultured alone or with autologous CD14-, CD4+, CD8+ or 
CD14-CD4-CD8- cells (data not shown). Nevertheless, this demonstrates that inactivated 
Vaccinia virus by itself can strongly induce IL-6, therefore having a potent effect by itself on 
T cells.  In addition, IL-6 is known to induce in vivo migration of human primary T cells but 
only in the presence of extracellular matrix (Weissenbach et al., 2004), which can also be an 
obvious advantage for vaccination purpose. Nevertheless, IL-6 also directly favors the 
polarization of naïve CD4+ T cells to T helper 2 cells (Diehl et al., 2002a; Diehl et al., 
2002b), which could hinder T helper 1 effects induced by the virus. 
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Figure 34. Induction of IL-6 gene expression. 
4x106 CD14+ cells were infected with the replication-incompetent (PLUV) CD154rVV or 
control virus at 5 m.o.i. and cultured with 10x106 autologous CD14- cells. Non-infected cells 
(NI) were used as negative control. CD14+, CD4+ and CD8+ cells were sorted after 36 hours 
co-culture using microbeads technology, and IL-6 gene expression was analyzed by 
quantitative real-time PCR. Data were expressed as ratio to CD154rVV infected samples. 
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3.3.2. Cytokines genes expression in directly infected monocytes derived iDC 
 
Dendritic cells (DC) are the most potent type of APCs and are responsible for the 
initiation of immune responses. Located in peripheral tissues and in lymphoid organs, DCs 
are only suited to detect and capture pathogens. Upon maturation, especially through TLR 
signaling (Akira et al., 2001), DC are upregulating MHC and costimulatory molecules and 
expressing pro-inflammatory cytokines. As a result, DC acquire the ability to prime naïve T 
cells (Cella et al., 1997). For these reasons, we were interested in evaluating the impact of 
CD154rVV on DC, especially immature DC. 
Monocyte derived iDC from healthy donors were infected with CD154rVV or with 
control virus at different m.o.i.. Untreated iDC were used as additional control. As shown in 
figure 35, IL-12p40 and GM-CSF gene expression were induced by CD154rVV infection but 
not by Control virus. In addition, TNF-α and IL-15 gene expression was found to be 
significantly higher in iDC infected with CD154rVV as compared to control virus.  
Figure 35. Induction of cytokine genes expression in CD14+ derived iDC. 
2 x 106 CD14+ derived iDC were infected with the replication-incompetent (PLUV) 
CD154rVV or control virus at 3 or 10 m.o.i., washed and cultured in complete medium 
supplemented with 10 % FCS. Cells were harvested 24 hours after infection. Gene 
expression was analyzed by quantitative real-time PCR and data were expressed as 
ratio to the CD154rVV 3 m.o.i. sample. Symbols (∗) indicate values significantly (p< 
0.05) different as compared to control VV infected cultures. 
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3.3.3. Indirect APC stimulation: cytokine genes expression in PBMC after 
coculture with autologous CD154rVV infected fibroblasts  
 
Intradermal injection of VV is likely to result in infection of fibroblasts. Thus, we 
were interested in indirect effects of fibroblast infection on uninfected immunocompetent 
cells.  
Primary skin fibroblasts were infected either with CD154rVV, or with WT virus, and 
co-cultured with autologous total PBMC. Cytokine genes expression was evaluated 48 hours 
after infection. As shown in figure 36, consistent with results obtained in directly infected 
APC (see above), IL-12p40 mRNA expression was strongly induced upon CD154rVV 
infection. Furthermore, background expression of IFN-γ and IL-2 genes in PBMC co-cultured 
with WT infected fibroblasts, was increased following CD154rVV infection. Thus, CD154 
signaling provided by infected bystander cells (here fibroblasts) is sufficient to induce strong 
APC activation and Th1 cytokine gene expression.  
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Figure 36. Genes expression in PBMC co-cultured with autologous infected skin 
fibroblasts. 
2.5 x 105 cultured Human Primary Skin fibroblasts were infected with the replication-
incompetent (PLUV) CD154rVV or control virus at 10 m.o.i., washed and cocultured for 48 
hours with 4 x 106 autologous PBMC. Non infected (NI) skin fibroblasts and PBMC cultured 
alone were used as controls. Gene expression was analyzed by quantitative real-time PCR and 
expressed as ratio to CD154rVV infected sample, as reference. IL-12p40 (A.), IFN-γ (B.), IL-
2 (C.) gene expression. Symbol (∗) indicates values significantly (p< 0.05) different between 
CD154rVV and  control VV infected cultures. 
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3.4. Blockage of CD154rVV effect by an antagonist anti-CD40 monoclonal antibody 
 
3.4.1. IL-12p40 gene expression inhibition 
 
Taken together, these data suggested strong CD40 triggering by CD154rVV infection 
on APC. In order to formally confirm whether these effects were indeed due to transgene 
expression, we performed similar experiments in the presence of an antagonist anti-human 
CD40 monoclonal antibody (generous gift from M. de Boer, Pan Genetics B.V., the 
Netherlands). This chimeric antibody was constructed by substituting mouse variable regions 
on a IgG4 human backbone (mAb ch5D12). This antibody was demonstrated to effectively 
inhibit a range of APC activities mediated by CD40/CD154 interaction (Laman et al., 2002).  
As shown in figure 37A, IL-12p40 gene expression induced in CD154rVV infected 
CD14+ cells was indeed abolished in the presence of anti-CD40 mAb, whereas it was not 
affected by the presence of a control antibody, formally demonstrating that effects observed 
with CD154rVV are due to transgene expression. 
 
3.4.2. IL-12 protein inhibition 
 
These data were also confirmed at the protein level. As shown in figure 37B, the 
functional IL-12p70 heterodimer was only detected in the supernatant of  CD154rVV infected 
CD14+ cells, but not in the supernatants of control VV infected CD14+ cells. Furthermore, 
IL-12 secretion induced by CD154rVV was fully prevented by the addition of anti-CD40 
monoclonal antibody (mAb ch5D12), but was not affected by a control antibody. These data 
confirm that CD154rVV is able to induce IL-12p40 gene transcription resulting in IL-12p70 
protein production in CD40+ infected cells due to functional ligand expression. 
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Figure 37. Inhibition of IL-12 expression induction in infected CD14+ cells, by an antagonist anti-
CD40 monoclonal antibody. 
2 x 106 CD14+ cells were infected with the replication-incompetent (PLUV) CD154rVV or control virus at 
10  m.o.i. and cultured overnight, in the presence or absence of mAb ch5D12 (10 µg/ml), a chimeric anti-
human CD40 monoclonal antibody were the mouse variable regions were placed on a IgG4 human backbone 
(provided by PanGenetics B.V., Utrecht, The Netherlands), or with an IgG mAb used as control. Non 
infected cells (NI) were used as negative control. (A.) Inhibition of  IL-12p40 gene expression induction was 
analyzed by quantitative real-time PCR and expressed as ratio to a reference sample (infection with 
CD154rVV at 10 m.o.i. without any mAbs). (B.) Inhibition of IL-12p70 secretion was analyzed by ELISA. 
Symbol (∗) refers to significant (p< 0.05) differences as compared to control VV infected cultures. 
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3.5. APC activation and iDC maturation 
 
3.5.1. Monocytes activation 
 
3.5.1.1. CD80 and CD86 as activation markers 
 
APC activation by direct infection resulting in CD40 cross ligation, is often 
characterized by an increased surface expression of costimulatory and MHC molecules. We 
therefore chose to monitor monocyte activation by following expression of CD80, CD86, and 
HLA-DR, on the surface of infected CD14+ cells.  
Monocytes from healthy donors were infected with CD154rVV or with WT virus as 
control virus, and effects on surface markers expression were evaluated in comparison to non 
infected cells. As shown in figure 38, in 1 day infected monocytes, CD86 and CD14 
expression are already clearly increased and downregulated respectively, in CD154rVV 
infected cells as compared to non infected monocytes and cells infected with the control virus. 
In contrast, CD80 and CD1a remained unmodified at that time point.  
 Similar results were observed at 4 days after infection: CD80 and CD86 expression 
induced by control virus (Mean Fluorescence Intensity or MFI = 15.9 and 681.2 respectively 
as compared to MFI = 3.1 and 605.7 respectively for NI cells), were enhanced in CD154rVV 
infected CD14+ cells (MFI = 19.7 and 839.1 respectively). On the other hand, CD14 
downregulation induced by control virus (MFI = 589.0 as compared to MFI = 603.9 for NI), 
was strongly enhanced in CD154rVV infected CD14+ cells (MFI = 346.3). However, 
CD154rVV infection did not appear to promote differentiation of CD14+ cells into iDC since 
no CD1a upregulation was observed.  
  
 
86 
A. 
985.4 4.0 284.0 2.2
N
I 
486.3 3.1 669.9 6.7
C
D
15
4r
V
V
 
10
 
m
.
o
.
i. 
555.0 1.9 622.5 4.7
C
o
n
tr
o
l V
V
 
10
 
m
.
o
.
i. 
CD14 CD1a CD86 CD80 
Figure 38.  Phenotypic analysis of infected CD14+ cells.  
2 x 106 human CD14+ cells from an healthy donor were infected with the replication-
incompetent (PLUV) CD154rVV or control virus at 10 m.o.i., washed and cultured for 
1 (A.) or 4 days (B.). Non infected CD14+ cells (NI) were also studied. Cells were 
stained either with Isotype control antibodies (thin line), or with specific antibodies 
(thick line). Relevant mean channel fluorescence intensities were calculated by 
subtracting the mean fluorescence corresponding to isotype control values, and are  
indicated on each panel. 
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3.5.1.2. HLA-DR as activation marker 
 
Monocyte activation following infection is characterized by MHC molecules up-
regulation. Similarly, CD40 ligation on APC is known to trigger ICAM-1 expression. Thus, to 
further confirm monocyte activation following CD154rVV infection, we also verified MHC 
and ICAM-1 expression on infected CD14+ cells surface.  
Figure 39 displays HLA-DR surface expression on infected monocytes. Infection with 
PLUV Vaccinia virus induces for one part of the population, already upon 12 hours infection, 
HLA-DR up-regulation as compared to non infected monocytes. This expression increases 
over time and concerns almost 100% of the population after 48 hours infection, as opposed to 
LPS activation which decreases rapidely after 24 hours stimulation. Nevertheless, no 
differences were observed between the Control virus and the CD154rVV. 
Indeed, no significant differences were observed between CD154rVV and Control 
virus regarding MHC class I molecules and ICAM-1 expression, probably because of  the 
already strong effect of the virus itself.  
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3.5.1.3. Inhibition of activation markers expression by an antagonist anti-
CD40 monoclonal antibody 
 
Taken together, these data suggested that CD154rVV was able to induce monocyte 
activation. As for cytokine gene expression, in order to formally confirm whether these 
effects were indeed due to transgene expression, we performed similar experiments in the 
presence of an antagonist anti-human CD40 monoclonal antibody. 
As shown in figure 40, CD80 and CD86 surface expression induced in CD154rVV 
infected CD14+ cells was indeed abolished in the presence of anti-CD40 mAbs, while not 
affected by the presence of a control antibody (not shown) demonstrating that effects 
observed with CD154rVV were due to CD40 triggering following transgene expression. 
Figure 39. Flow cytometry analysis of the cell surface expression of HLA-DR as activation 
marker in infected CD14+ cells. 
6 x 106 human CD14+ cells from an healthy donor were infected with the replication-
incompetent (PLUV) CD154rVV or control VV at 4 m.o.i., washed and cultured for 48 hours. 
Non infected cells (NI) and cells cultured with LPS (1 µg/ml) were used as negative and positive 
controls, respectively. Cells were stained at different time points either with Isotype control 
antibodies, or with FITC-labeled anti-HLA-DR mAbs, washed, fixed with paraformaldehyde 
1%, and subsequently analyzed by flow cytometry. 
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Figure 40. Inhibition of cell surface expression of activation markers in infected CD14+ cells, by 
an antagonist anti-CD40 monoclonal antibody.  
1.5 x 106 human CD14+ cells from an healthy donor were infected with the replication-incompetent 
(PLUV) CD154rVV or control virus at 10 m.o.i., wash and cultured for 4 days. Non infected CD14+ 
cells (NI) and cells cultured with 1 µg/ml LPS were also studied. Cells were stained with specific 
antibodies: FITC-labeled anti-CD86 mAbs and PE-labeled anti-CD80 mAbs, washed, fixed with 
paraformaldehyde 1%, and subsequently analyzed by flow cytometry. 
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3.5.2. iDC activation and maturation 
 
Maturation of iDC is crucial for the initiation of cellular immune response. Levels of 
CD86 and CD83 surface expression (Banchereau et al., 1998) were evaluated as markers of 
activation and maturation of monocyte derived iDC from healthy donors. Since iDC seem to 
be more sensitive to viral infection than CD14+ cells (see apoptosis results), low viral dose (1 
m.o.i.) was chosen to evaluate the impact of CD154rVV on iDC. However, since low viral 
doses result in lower transgene expression, prolonged culture times (5 days) were necessary 
prior to phenotypic analysis. In these conditions, low dose CD154rVV infection of iDC 
resulted in activation and maturation, as indicated by enhanced CD86 and “de novo” CD83 
expression, as compared to WT infection (Figure 41).  
Figure 41.  Flow cytometric analysis of the cell surface expression of CD83 and CD86 in 
infected CD14+ derived iDC.  
2 x 106 CD14+ derived iDC from an healthy donor were infected with the replication-incompetent 
(PLUV) CD154rVV or control virus at 1 m.o.i., washed and cultured for 5 days in complete 
medium supplemented with 10% FCS. Non infected CD14+ cells (NI) were also used as additional 
control. Cells were harvested and stained with anti-CD83 or anti-CD86 mAbs. Staining of the cells 
under investigation with isotype control mAb showed identically negative profiles in all cases (data 
not shown). Mean Fluorescence Intensities are indicated in brackets. 
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4. Effects of APC activation by CD154rVV on T cell responses 
 
4.1. Induction of T cell response to viral antigen 
 
4.1.1. Cytokine gene expression 
 
The above data prompted us to explore the effects of CD154rVV on antigen 
presentation to T cells, using Vaccinia virus specific responses as read-out. Peripheral blood 
CD14+ cells from Vaccinia immunized healthy donors were infected with CD154rVV or 
Control virus, incubated in complete medium for 24 hours and subsequently co-cultured with 
autologous CD14- cells.  
Total cellular RNA was reverse transcribed and T helper 1 cytokines gene expression 
were quantified by real-time quantitative PCR (qRT-PCR). As shown in figure 42A, 
expression of IFN-γ and IL-2 genes readily induced by the control virus, was found to be 
significantly increased following CD154rVV infection of APC, conspicuously at low moi. 
Interestingly, the expression of these cytokines genes appeared to be lower in this directly 
infected APC setting as compared to experiments using “indirect” APC stimulation by 
infected fibroblasts, thus suggesting that in vivo, fibroblasts infected during immunization 
could have a beneficial effects on T cell responses.   
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Figure 42. Evaluation of T cell response to viral antigen. 
(A.) Induction of IL-2 and IFN-γ gene expression in CD14- cells cocultured with autologous infected CD14+ 
cells. 106 CD14+ cells from a vaccinia immune donor were infected with the replication-incompetent (PLUV) 
CD154rVV or control virus at 1 or 4  m.o.i., washed and co-cultured overnight with 106 autologous CD14- cells. 
Non infected cells (NI) were also used as control. Gene expression was analyzed by quantitative real-time PCR 
and data were expressed as ratio to those detected upon infection with CD154rVV at 1 moi. Proliferation of 
purified CD4+ (B.) and CD8+ T cells (C.) in the presence of autologous infected CD14+ cells. 105 CD14+ cells, 
freshly obtained from a vaccinia immune donor, were infected with the replication-incompetent (PLUV) 
CD154rVV or control virus at 10 m.o.i., wash and cocultured with autologous T cells (CD4+: 3 x 105 , CD8+: 2,5 
x 105 per well). Co-culture with non infected CD14+ cells (NI) was used as negative control. After 5 days, 0.5 
µCi of [methyl 3H]thymidine were added to each well for the following 16 hours of the incubation period. Error 
bars represent the standard deviation of the mean cpm of triplicate cultures. Symbol (∗) indicates values 
significantly (p< 0.05) different between CD154rVV and  control VV infected cultures. 
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4.1.2. T cell proliferation 
 
In previous work we have shown that MHC class II Vaccinia virus specific CD4+ T 
cells from Vaccinia immunized donors respond to VV by active proliferation (Marti et al., 
1997). Thus, effects of CD154rVV infected APC on CD4+ T cell proliferation were explored 
using the virus itself as antigen in freshly isolated cells from vaccinated healthy donors. As 
shown in figure 42B, CD4+ T cell proliferation was significantly enhanced upon APC 
infection with CD154rVV as compared to Control virus. Even if the differences are not 
statistically significant, we observed in several experiments that CD8+ T cell proliferation 
seemed marginaly enhanced upon APC infection with CD154rVV as compared to control 
virus (figure 42C). 
These results were confirmed using CFSE staining as method for proliferation 
quantification. Monocytes from a Vaccinia immunized healthy donor were infected either 
with CD154rVV or with the Control virus at 4 m.o.i.. Non infected (NI) and PHA (1 µg/ml) 
stimulated cultures were used as negative and positive control, respectively. Monocytes were 
co-cultured for 5 days with CFSE stained autologous CD14- cells. CD4+ T cell proliferation 
was evaluated by FACS staining. A shown in figure 43, PHA induced strong CD4+ T cells 
proliferation as opposed to the marginal proliferation induced with non infected CD14+. 
Interestingly, once again, CD4+ T cell proliferation was manifestly enhanced upon APC 
infection with CD154rVV as compared to Control virus. 
Figure 43. Confirmation of CD4+ T cell proliferation response to antigen. 
Proliferation of CD4+ cells in the presence of autologous infected CD14+ cells was evaluated by 
FACS staining. 2x106 CD14+ cells, freshly isolated from a vaccinia immune donor, were infected 
with the replication-incompetent (PLUV) CD154rVV (—) or control virus (—) at 4 m.o.i., wash and 
co-cultured with 2x106 autologous CD14- cells. Co-culture with non-infected CD14+ cells (—) and 
co-culture with PHA (1µg/ml) (—) were used as negative and positive control, respectively. 
Proliferation was evaluated after 5 days culture by staining with PE-labeled CD4 and CFSE and flow 
cytometry analyze. 
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4.2. CD154rVV promotes APC capacity to prime antigen-specific CTL response 
 
In previous work, we have shown that rVV encoding co-stimulatory molecules 
provide powerful adjuvance to the induction of specific cytotoxic T-cell responses, with 
particular reference to tumor associated antigens (Zajac et al., 1998; (Zajac et al., 2003). The 
capacity of CD154rVV infected APC to enhance specific MART-1/Melan-A specific CTL 
stimulation in vitro was then tested. Monocytes derived iDC from healthy HLA-A0201+ 
donors were infected with CD154rVV or WT as control, and mixed with autologous CD8+ T 
cells in the presence of MART-1/Melan-A27-35 melanoma associated epitope provided as 
soluble peptide.  
As shown in figure 44A.1, on day 11, after the priming, specific tetramer staining did 
not detect major differences among the cultures under investigation. In contrast, the 
enhancing effect of CD154rVV activation on CTL priming became dramatically evident after 
a first and particularly after a second boost. Indeed, cultures primed with CD154rVV infected 
APC displayed 13.84% HLA-A0201/MART-1/Melan-A27-35 tetramer positive CD8+ T cells, 
as compared to 2.26% in non-infected conditions, and 1.59% in cultures where APC were 
infected with control VV (figure 44A.2). The cytotoxic capacity (figure 44B) of these cultures 
was confirmed by standard chromium release assays.  
Similar results were obtained using CD14+ cells as APC (figure 45). Indeed, the 
cultures infected with CD154rVV displayed 3.80% tetramer positive cells, as compared to 
0.44% in non-infected condition, and 0.79% in cultures where APC were infected with 
control virus.  
Same results were obtained by using other peptides (EBV BMLF1, EBV LMP2, 
CMVpp65) and monocytes as APC (Figure 46): after 7 only days, cultures primed with 
CD154rVV infected CD14+ cells already displayed usually higher percentage of peptide-
specific CTL as compared to infected cultures, or cultures primed with control virus.  
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Figure 44. Induction of MART-1/Melan-A27-35-specific CD8+ T cells using infected iDC as 
APC. 
2.7 x 105 iDC were infected with the replication-incompetent CD154rVV or control virus (PLUV) at 
8 m.o.i., washed and co-cultured with 5 x105 autologous CD8+ T cells. Non infected (NI) iDC were 
also used as control. 10 µg per ml of MART-1/Melan-A27-35 peptide were added to all cultures. 
Cells were cultured for 25 days, and regularly supplemented from day 8 on with medium containing 
a final concentration of 10 U/ml of IL-2. Furthermore, cultures were restimulated on days 12 and 19 
using 20 µg/ml peptide-pulsed and irradiated autologous EBV-BL resuspended in complete medium 
supplemented with 10 U/ml IL-2. (A.) Flow cytometric analyses of CD8+ T cells were performed at 
day 11 and day 25, before the first boost (A.1.) and after the second boost (A.2.) respectively, by 
staining with FITC-labeled anti-CD8 mAbs and PE-labeled specific MART-1/Melan-A27-35-HLA-
0201 tetramer. (B.) Chromium-release assays were performed, at the indicated effector-to-target 
ratios, by using as targets, MART-1/Melan-A27-35-peptide (20 µg/ml)-pulsed HLA-0201+ EBV-BL. 
CTL generated upon stimulation with the MART-1/Melan-A27-35-peptide alone (), or with 
CD154rVV (■) or with control virus (▲) were tested. Standard deviations, never exceeding 10% of 
the reported values,are not shown. 
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Figure 45. Induction of MART-1/Melan-A27-35-specific CD8+ T cells using infected CD14+ 
cells as APC. 
5 x 105 CD14+ cells were infected with the replication-incompetent CD154rVV or control virus 
(PLUV) at 8 m.o.i., washed and co-cultured with 6 x105 autologous CD8+ T cells. Non infected 
(NI) CD14+ cells were also used as control. 10 µg per ml of MART-1/Melan-A27-35 peptide were 
added to all cultures. Cells were cultured for 25 days, and regularly supplemented from day 8 on 
with medium containing a final concentration of 10 U/ml of IL-2. Furthermore, cultures were 
restimulated on days 12 and 19 using 20 µg/ml peptide-pulsed and irradiated autologous EBV-BL 
resuspended in complete medium supplemented with 10 U/ml IL-2. Flow cytometric analyzes of 
CD8+ T cells were performed at day 11 and day 25, before the first boost (A.1.) and after the 
second boost (A.2.) respectively, by staining with FITC-labeled anti-CD8 mAbs and PE-labeled 
specific MART-1/Melan-A27-35-HLA-0201 tetramer.  
0.79% 
A.1. A.2. 
Control VV 
CD154rVV 
NI 
Day 11 
1.63% 
0.27% 
0.39% 
Day 25 
0.44% 
3.80% 
  
 
98 
 
 
 
 
 
 
 
Figure 46. Induction of other antigen-specific CD8+ T cells using infected CD14+ cells as APC. 
2 x 106 CD14+ cells were infected with the replication-incompetent CD154rVV or Control VV (PLUV) 
at 10 m.o.i., washed and co-cultured with 2 x 106 autologous CD8+ T cells. Non infected (NI) CD14+ 
cells were also used as control. 10 µg per ml of peptide (EBV BMLF1, EBV LMP2, CMVpp65 or 
MART-1/Melan-A27-35) were added to the cultures. Cells were cultured for 7 days in complete medium 
without any IL-2 supplementation. Flow cytometry analyzes of CD8+ T cells were performed on day 7, 
by staining with FITC-labeled anti-CD8 mAbs and PE-labeled peptide specific tetramer. 
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DISCUSSION 
 
Innovative approaches have to be created to cure patients with tumor burden. Even if 
immunological approaches are actually tested with late stage cancer, they are probably most 
appropriate for early stages tumor or after resection, with high risk of recurrence. One 
promising approach seems to be the generation of therapy stimulating specific tumor-directed 
immune response, combined with non specific immune-modulation. For this purpose, 
efficient presentation of immunogens to T cells, leading to generation of a large numbers of 
Tumor Associated Antigen (TAA) specific cytotoxic T cells (CTL), represents a critical issue 
in cancer immuno-therapy. Nevertheless, even if this method seems promising, the overall 
clinical success of this experimental approach in cancer patients remains limited, to date. 
Indeed, paradoxically, T cell activation as detected ex vivo, does not always correlate with 
clinical response (Nielsen et al., 2000). Current approaches obviously need to be improved. 
The intrinsic properties of poxvirus, especially Vaccinia virus, render this virus highly 
interesting as a vaccine vector (Moss, 1996). It is one of the most frequently used in modern 
cancer immunotherapy. It has been employed as a vector for many tumor antigens like 
Carcinoembryonic Antigen Epitopes (CEA) (Tsang et al., 1995) or Tyrosinase (Yee et al., 
1996). In addition, molecular characterization of HLA restricted epitopes lead to an improved 
formulation of the vaccine (Celis et al., 1995).  
Our group’s main focus is the development of an anti-cancer therapeutic approach 
through the generation of tumor specific cytotoxic T cell responses in melanoma patients. As 
principal vaccine vector, we are using recombinant Vaccinia virus expressing melanoma 
tumor associated antigens (gp100, MART-1/Melan-A27-35, Tyrosinase1-9) in combination with 
co-stimulatory molecules: CD80 and CD86. This vaccine was used in a phase I/II clinical trial 
(Zajac et al., 2003) and resulted in a substantial immunogenic response. 
Nevertheless, even if the specific response to TAA was frequently enhanced after 
vaccination, these responses were mild and transient. 
Therefore, further investigation on vector providing ligands for stimulatory pathways 
susceptible to increase or at least to maintain vaccine driven TAA specific CD8+ T cell 
response in cancer patients appears to be a critical issue. As an interesting new immunogenic 
vaccine, a recombinant Vaccinia virus expressing CD154, known to play a major role in the 
activation of different help-dependent immune responses, was constructed and evaluated in 
vitro. 
Activation of specific T cell responses, especially for tumor antigens, do require more 
signals than the antigenic peptide restricted by the MHC class I molecule and recognized by 
the T cell receptor (Matzinger, 2002). In order not to lead to anergy but to T cell activation, 
this signal must be followed by a second one generated by co-stimulatory molecules, such as 
CD80 and CD86. This signal can be reinforced by a third signal mediated by soluble factors 
such as cytokines (for instance IL-12, IL-15), which are usually resulting from activation of 
“helper mechanisms”. Among CD4+ driven help, activation of APC through CD40/CD154 is 
a major pathway. Indeed, this co-receptor, expressed on activated CD4+ T cells and, upon 
binding CD40 expressed on APC, has been reported to increase their antigen presentation and 
immunomodulatory capacities, in particular through the expression of T helper 1 cytokines. 
Underlying this mechanism, CD40 cross-linking has been shown to bypass the absolute 
requirement for CD4+ T cells in CTL generation (Bennett et al., 1998; Ribas et al., 2001; 
Toes et al., 1998). CD40/CD154 interaction controls APC function by upregulating 
expression of costimulatory ligands, MHC molcules and multiple cytokines (Grewal et al., 
1998) such as IL-12 and IL-15 playing important roles in CTL induction and homeostatic 
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expansion (Banchereau et al., 1994; Bourgeois et al., 2002; Curtsinger et al., 1999; Curtsinger 
et al., 2003; Ha et al., 1999; Kieper et al., 2001; Kuniyoshi et al., 1999; Maruo et al., 1997; 
Shu et al., 1995).  
Based on our previous experience with recombinant Vaccinia virus and 
immunomodulation, we hypothezised that a recombinant Vaccinia virus expressing CD154 
may reproduce this mechanism and ultimately optimize CTL generation and activation. 
CD154 gene was first cloned from human PHA stimulated PBMC. A mutagenesis step 
was required because the CD154 sequence contained two TTTTTNT sequences, known to be 
STOP sequence for Vaccinia virus early transcription. The mutated CD154 gene was then 
inserted in the A56R locus of Wild Type Vaccinia virus (Copenhague strain) genome by 
homologous recombination. 
In the perspective of eventual human application where safe vectors are preferred, the 
potency of CD154rVV was evaluated in a non replicative form. Replication was inactivated 
by treatment with psoralen and long wave UV (PLUV), inducing cross-linking in genomic 
DNA. Because early phase of viral transcription is not affected, the resulting virus is non 
replicating, thus less cytopathic, but still expresses inserted gene under viral promoters 
control. 
At first, the level of CD154 expression over time was characterized in cells infected 
with PLUV CD154rVV. Indeed, following transient T cell receptor triggering of CD4+ T 
cells in vitro, CD154 surface expression is peaking 8 hours following activation and is then 
rapidly down-regulated (Yellin et al., 1994b). In contact with PLUV Vaccinia virus infected 
monocytes, CD4+ T cells activation, as demonstrated  by an increase in CD154 expression, 
remains detectable up to 36 hours infection. At that time point, CD154 expression, in infected 
monocytes, was still marked. Thus, CD154 expression seems longer and stronger in 
CD154rVV infected monocytes as compared to MHC class II activated CD4+ T cells. This 
observation could already be an advantage of expressing CD154 with a recombinant Vaccinia 
virus, whereas the longer infected cells are strongly expressing CD154, the more this 
molecule could induce APC’s activation and subsequently enhance T cell activation.  
The effects of CD154rVV infection on CD40+ cells endowed with antigen presenting 
capacity were further investigated. We were able to show that replication incompetent 
CD154rVV induced a marked cytokine secretion upon APC infection, especially IL-12 and 
IL-15, which are known to play major roles in CTL induction and in the maintainance of 
CD8+ T cell memory (Fehniger et al., 2001; Jonuleit et al., 1997; Lu et al., 2002; Wilkinson 
et al., 1995). Indeed, IL-12p40 transcription in monocytes was exclusively detected in the 
presence of CD154rVV infected cells. GM-CSF and TNF-α gene expression were induced 
following APC infection with Control virus but to significantly lower levels as compared to 
those observed upon CD154rVV infection. Similarly, IL-12p40 and GM-CSF transcription in 
monocytes derived iDC were as well exclusively detected following CD154rVV infection, 
and TNF-α gene expression is significantly higher with CD154rVV as compared to the 
Control virus infection. Interestingly, we also show that IL-15 transcription is significantly 
higher in iDC infected with CD154rVV as compared to Control virus. 
These cytokines inductions in APC upon CD154rVV stimulation are of major interest. 
Previous study showed that CD40 ligation on APC, and notably on DC, triggers production of 
high level of IL-12 (Cella et al., 1996), indicating that CD154rVV could notably enhance 
CD8+ T cells expansion and activation, through to IL-12 properties. For instance, IL-12 is 
known to play important role during CTL generation (Bourgeois et al., 2002; Kieper et al., 
2001; Kuniyoshi et al., 1999). Indeed, IL-12p40 is normally produced by activated CD14+ 
cells (Reiner et al., 1994; Skeen et al., 1996) and dendritic cells (Cella et al., 1996; Heufler et 
al., 1996; Macatonia et al., 1995). It may act as a chemotactic molecule for macrophages (Ha 
et al., 1999) and one of its major role is to enhance CD8+ T cell homeostatic expansion 
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(Kieper et al., 2001) and activation (Curtsinger et al., 1999; Curtsinger et al., 2003). IL-15 is 
expressed by DC, monocytes and macrophages (Fehniger et al., 2001; Jonuleit et al., 1997), is 
a potent chemoattractant for T cells (Wilkinson et al., 1995), and promotes long-term survival 
of anti-tumor cytotoxic T lymphocytes. One of its crucial role is also to stimulate the 
proliferation of human memory (CD45+RO+) CD4+ and CD8+ T cells (Kanegane et al., 
1996). Due to IL-15 characteristics, activation of CD40/CD154 on APC following infection 
by CD154rVV, should subsequently also play an important role in the survival of T cells and 
in the proliferation of tumor specific memory T cells.  
Similarly, GM-CSF increased expression following CD154rVV infection is of interest 
since this cytokine, secreted by monocytes and macrophages, is crucial for APC recrutment 
and development (Inaba et al., 1992). Our data confirmed a previous study demonstrating that 
CD40 stimulation with soluble CD154 induces pro-inflammatory responses in CD14+ cells, 
notably TNF-α (Kiener et al., 1995), which is also known to induce cells death, especially 
tumor cells (Carswell et al., 1975). 
The role of Vaccinia virus expressed CD154 was further confirmed by an antagonist 
chimeric anti-human CD40 monoclonal antibody (generous gift from M. de Boer, Pan 
Genetics B.V., Utrecht, The Netherlands). This antibody binds with high affinity (Kd = 
2.2x10-10) and blocks the CD40 receptor, effectively demonstrating the specific activity of 
CD154 in the activation of cells (de Vos et al., 2004). 
In this work, we have shown that a replication incompetent CD154rVV is able to 
induce a marked APC activation, due to CD40 receptor triggering within monocyte or iDC 
infected populations. Similarly, phenotypic characterization of infected CD14+ derived iDC 
suggests that inactivated CD154rVV is able to induce iDC maturation which is a crucial event 
for the initiation of cellular immune response, as verified by CD83 expression (Banchereau et 
al., 1998). Therefore, CD154rVV was thereby overcoming the intrinsic detrimental effects of 
WT VV. Indeed, previous studies have demonstrated that WT VV inhibits iDC maturation 
(Drillien et al., 2000; Engelmayer et al., 1999) whereas CD40 ligation promotes it 
(Banchereau et al., 1994; Larsson et al., 2001; Straw et al., 2003).  
As a consequence, these effects on APC are reflected by enhanced functions of T 
cells: especially CD4+ but also CD8+ T cell proliferation, IL-2 and IFN-γ expression were 
significantly increased in cultures stimulated with CD154rVV as compared to Control virus. 
Because IFN-γ activates monocytes, induces expression of MHC class II molecules and 
promotes directly T- and B- lymphocytes differentiation (Younes et al., 2002), CD154rVV 
might promote T lymphocytes differentiation and also have an indirect effect on tumor cell 
killing. 
Similar to natural situation of CD154 triggering by helper cells, the elicitation of these 
effects are not limited to direct immunocompetent cell infection. They can be mediated by 
bystander infected cells as fibroblasts, a situation likely occurring in vivo following 
intradermal injection. This was demonstrated by increased IL-12p40, IFN-γ and IL-2 gene 
expression in PBMC co-cultured with autologous human skin fibroblasts infected with 
CD154rVV as compared to Control VV infection. 
Most importantly, our data clearly indicate that CD154rVV provides efficient 
adjuvance during the induction of CTL specific for MART-1/Melan-A27-35 model TAA in the 
absence of CD4+ T cells, a function exquisitely mediated by APC licensing via CD40/CD154 
interaction (Bennett et al., 1997; von Herrath et al., 1996). Indeed, in cultures of infected APC 
with autologous CD8+ T cells and MART-1/Melan-A27-35 soluble peptide, the enhancing 
effects of CD154rVV activation on CTL priming became dramatically evident after 
restimulation, as measured with specific tetramer or by cytotoxicity. 
Taken together these data indicate that functional CD154 expression from recombinant 
Vaccinia virus infected cells induces APC activation thereby enhancing their capacity to 
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generate T cell immune responses. Since triggering of the CD40/CD154 pathway by 
CD154rVV efficiently mimics key features of activated helper T cells, this recombinant 
vector, active in non replicating form, may help bypassing their role in CTL induction, thus 
qualifying as a potentially relevant reagent in the generation of CD8+ T cell responses in 
cancer immunotherapy. 
 
Similarly, agonistic anti-CD40 mAbs, recombinant CD154 and CD154-transfected 
cells are already in use for experimental therapy of human cancer. For instance, clinical 
effects of recombinant CD154 protein were observed in the treatment of solid tumors and 
non-Hodgkin’s lymphoma. In phase I studies, soluble recombinant CD154 was administrated 
subcutaneously with encouraging anti-tumor activity including a long-term complete 
remission (Vonderheide et al., 2001; Younes, 2001). Nevertheless, potential risk of systemic 
inflammation and auto-immune consequences remains a concern for systemic CD154-based 
experimental therapy. In the same way, an adenoviral vector encoding CD154 was well 
tolerated, in phase I clinical trials using infusion of transduced autologous leukemia cells 
(Kipps et al., 2000; Wierda et al., 2000), in which increased number of leukemia-specific T 
cells as well as reduction in leukemia cell count and lymph node size was demonstrated. 
However, once again, potential side effects should be carefully evaluated, since patients 
treated with recombinant adenovirus expressing CD154 transduced leukemia cells commonly 
experienced Influenza-like symptoms (Kipps et al., 2000). Likewise, efficacy of agonistic 
CD40-reactive mAb for clinical applications was limited by pro-inflammatory cytokine 
production by CD40-activated endothelial cells (Singh et al., 2001). 
Nevertheless, CD154-based therapy alone or in combination with other therapies may 
offer an effective and safe strategy for the treatment of human cancers. The promise of 
CD154 as a tumor therapeutic agent to directly modulate tumor cell growth, and indirectly 
activate anti-tumor immune response, may just depend on the way of administration or on 
selective CD154 expression within tumor environment. 
Recombinant Vaccinia virus expressing CD154 seems in this regard a good candidate. 
Based on viral characteristics, PLUV CD154rVV should be safe and could, as demonstrated 
here, enable bystander cells to activate APC, resulting in enhanced CD8+ T cells priming. 
Because CD154 is only expressed at the surface of infected cells, side effects of systemic 
CD154 administration could also be limited. In addition, the use of a viral vector can prolong 
the expression of the recombinant protein as compared to soluble CD154, which is susceptible 
to rapid proteolysis as opposed to efficient presentation by MHC molecules loaded through 
the class I endogenous pathway of antigen processing (Maffei et al., 1997; Townsend et al., 
1986; van Endert, 1999). 
 
In order to further characterize the effects of CD154rVV on T cell response, we could 
analyze the phenotype of the CTL in condition primed with CD154rVV infected APC and 
peptide. Indeed, CTL can be classified in five distinct classes regarding the expression of 
CD45RA, CCR7, CD27, CD28 and CD62L (Champagne et al., 2001; Geginat et al., 2003; 
Tomiyama et al., 2002; Valmori et al., 2002). Antigenic stimulation of CD8+ T cells results in 
the expansion of naïve and central memory cells mainly (Champagne et al., 2001; Geginat et 
al., 2003). Similarly, CD154 binding to the CD40 expressed on APC (Moodycliffe et al., 
2000; Stout et al., 1996b; Stout et al., 1996a) results in an increase of T helper 1 cytokines 
such as IL-12 (Maruo et al., 1997) and IL-15 (Wilkinson et al., 1995), playing a major role in 
memory induction (Bourgeois et al., 2002; Judge et al., 2002; Kanegane et al., 1996; Kieper et 
al., 2001; Kuniyoshi et al., 1999; Yajima et al., 2002). In the same way, CD154 is known to 
play roles in maintenance of T cell memory (Borrow et al., 1996; Huster et al., 2004; 
Koschella et al., 2004; Rogers et al., 2003). Due to these properties, we wanted to 
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demonstrate in vitro, that CD154rVV is able to favor memory CD8+ T cell enhancement. 
Some preliminary results seem to demonstrate that PLUV CD154rVV is able to effectively 
enhance  antigenic peptide specific CD8+ T cells, with in majority central memory phenotype 
and in some case effector memory or naïve phenotype.  
Finally, it may be of interest to evaluate in vitro the potential synergy of CD154 with 
other co-stimulatory molecules such as CD80/CD86 expressed by recombinant virus. Indeed, 
recombinant poxvirus expressing immunomodulatory molecules (CD80 and CD86) was 
demonstrated in vitro and in vivo to enhance the immunogenic capacity of a recombinant 
Vaccinia virus encoding different tumor associated antigens (Marti et al., 1997; Zajac et al., 
1997). rVV encoding Mart-1/Melan-A27-35, Gp100 and Tyrosinase1-9 Tumor Associated 
Antigens and with CD80 and CD86 (Oertli et al., 2002; Spagnoli et al., 2002) has been 
successfully used in a phase I/II clinical trial (Zajac et al., 2003). Nevertheless, even if 
specific responses to TAA were often induced after vaccination, these responses were limited 
in time and in intensiy. Properties of CD154rVV demonstrated in this work, may eventually 
improve the intensity and the duration of these T cell responses. 
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